# Mitigation of chemotherapy-induced gut dysbiosis and diarrhea by supplementation with heat-killed Bacteroides fragilis.

<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Med</journal-id><journal-id journal-id-type="iso-abbrev">BMC Med</journal-id><journal-title-group><journal-title>BMC Medicine</journal-title></journal-title-group><issn pub-type="epub">1741-7015</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmcid">12235877</article-id><article-id pub-id-type="pmid">40624638</article-id>
<article-id pub-id-type="publisher-id">4233</article-id><article-id pub-id-type="doi">10.1186/s12916-025-04233-5</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Mitigation of chemotherapy-induced gut dysbiosis and diarrhea by supplementation with heat-killed <italic>Bacteroides fragilis</italic></article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Yan</surname><given-names>Xinwen</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Lin</surname><given-names>Xinlong</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Jianhua</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Zheng</surname><given-names>Lijun</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Yangyang</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Fang</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Ying</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lu</surname><given-names>Yishi</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Chongyang</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Shen</surname><given-names>Binhai</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Hongbin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Ruo</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hou</surname><given-names>Fengyi</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Qian</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Song</surname><given-names>Mengyao</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Ke</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zhu</surname><given-names>Fangqing</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Sheng</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Yuqing</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Wei</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Ping</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Liao</surname><given-names>Wangjun</given-names></name><address><email>nfyylwj@163.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Zhi</surname><given-names>Fachao</given-names></name><address><email>zhifc41532@163.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01eq10738</institution-id><institution-id institution-id-type="GRID">grid.416466.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 959X</institution-id><institution>Guangdong Provincial Key Laboratory of Gastroenterology, Institute of Gastroenterology of Guangdong Province, Department of Gastroenterology, </institution><institution>Nanfang Hospital, Southern Medical University, </institution></institution-wrap>Guangzhou, 510515 China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01eq10738</institution-id><institution-id institution-id-type="GRID">grid.416466.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 959X</institution-id><institution>Department of Oncology, </institution><institution>Nanfang Hospital, Southern Medical University, </institution></institution-wrap>Guangzhou, 510515 China </aff><aff id="Aff3"><label>3</label>Guangzhou ZhiYi Biotechnology Co. Ltd, Guangzhou, 510530 China </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03cyvdv85</institution-id><institution-id institution-id-type="GRID">grid.414906.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 1808 0918</institution-id><institution>Department of Gastroenterology, </institution><institution>First Affiliated Hospital of Wenzhou Medical University, </institution></institution-wrap>Wenzhou, 325000 China </aff></contrib-group><pub-date pub-type="epub"><day>7</day><month>7</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>7</day><month>7</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>23</volume><elocation-id>408</elocation-id><history><date date-type="received"><day>22</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>19</day><month>6</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par7">The role of gut microbial dysbiosis in chemotherapy-induced diarrhea (CID) pathogenesis remains unclear in humans. This study investigates gut microbiota alterations in CID patients and evaluates the therapeutic potential of probiotic supplementation.</p></sec><sec><title>Methods</title><p id="Par8">To establish a paired cohort for longitudinal comparison and minimize confounding factors in assessing CID-related microbiota changes, strict inclusion/exclusion criteria were applied to gastrointestinal cancer patients. Fecal samples from eligible participants underwent shotgun metagenomic sequencing to comprehensively profile the gut microbiome composition and function. To evaluate probiotic efficacy and mechanisms, we utilized 6&#x02013;8-week-old male BALB/c and C57BL/6 mice in established 5-FU- or CPT-11-induced CID models. Probiotic efficacy was assessed using primary (diarrhea severity) and secondary endpoints (body weight change, intestinal permeability). Mechanistic studies were conducted in murine models, complemented by IEC-6 cells and intestinal organoid experiments to elucidate microbiota-host interactions.</p></sec><sec><title>Results</title><p id="Par9">Analysis of paired fecal samples (pre- and post-chemotherapy) from 30 gastrointestinal cancer patients (<italic>n</italic>&#x02009;=&#x02009;60) revealed chemotherapy-induced reduction of <italic>Bacteroides fragilis</italic> (<italic>B. f</italic>) via metagenomics sequencing, with baseline <italic>B. f</italic> relative abundance negatively correlating with CID severity (<italic>r</italic>&#x02009;=&#x02009;&#x02009;&#x02212;&#x02009;0.93, <italic>p</italic>&#x02009;=&#x02009;3.1e&#x02009;&#x02212;&#x02009;12). Building on these clinical observations, in 5-FU/CPT-11-induced CID murine models, oral gavage of heat-killed <italic>B. f</italic> (<italic>hk-B. f</italic>) outperformed live bacteria in diarrhea alleviation. Mechanistically, <italic>B. f</italic>-derived succinate exacerbated diarrhea, while its capsular polysaccharide (PSA) ameliorated mice diarrhea. This discovery explains the discrepant therapeutic effect between <italic>hk-B.&#x000a0;f</italic> and live <italic>B.&#x000a0;f</italic>. Fluorescence tracing confirmed <italic>hk-B. f</italic> transiently localized to the upper gastrointestinal tract without extraintestinal colonization. <italic>hk-B. f</italic> preserved epithelial integrity, mitochondrial function, and intestinal organoid development (higher budding count and larger organoid surface area). Moreover, <italic>hk-B.&#x000a0;f</italic> upregulated the expression of BCL2 and downregulated the expression of BAX. Shifting the balance between BCL2 and BAX alleviates intestinal epithelial apoptosis. Caspase-3 inhibition or BCL2 silencing abrogated <italic>hk-B. f</italic>&#x02019;s anti-apoptotic effects in IEC-6 cells.</p></sec><sec><title>Conclusions</title><p id="Par10">Pathological process of CID can be partially explained by compositional alterations in the gut microbiota. Supplementation with <italic>hk-B.&#x000a0;f</italic> reduces 5-FU-stimulated epithelial injury through mitochondrial apoptotic pathway in CID murine models. These preclinical findings suggest <italic>hk-B.&#x000a0;f</italic> merits further investigation as a potential strategy for improving CID, pending clinical validation.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12916-025-04233-5.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Chemotherapy</kwd><kwd>Diarrhea</kwd><kwd>Probiotics</kwd><kwd><italic>Bacteroides fragilis</italic></kwd><kwd>Mitochondria</kwd><kwd>Apoptosis</kwd></kwd-group><funding-group><award-group><funding-source><institution>Study on the Mechanism of FUT7 regulating CD15s+eTreg cells in the Pathogenesis of Ulcerative Colitis</institution></funding-source><award-id>Y20190159</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>Key Technology Project in Guangzhou</institution></funding-source><award-id>NO.2024B03J1282</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>Innovation Leading Team Project in Guangzhou</institution></funding-source><award-id>NO. 201809010014</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par34">Chemotherapeutic agents often cause gastrointestinal toxicity that may manifest as diarrhea, constipation, and mucositis, limiting patient tolerance and contributing to mortality [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. The risk for chemotherapy-induced diarrhea (CID) is significantly greater for chemotherapeutic regimens that include fluoropyrimidines, such as fluorouracil (5-FU) and irinotecan (CPT-11), with grade 3&#x02013;4 diarrhea reported in up to 47% of patients [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>].
</p><p id="Par35">Several reviews and guidelines have been published on CID; however, most studies have focused on symptomatic management rather than mitigation of the underlying pathophysiological mechanisms. Chemotherapeutic agents used for cancer treatment primarily target rapidly dividing cells [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR3">3</xref>], including cells of the gastrointestinal epithelium. These cells form a semipermeable barrier and are fundamentally important for maintaining the secretory, absorptive, and propulsive functions of the gastrointestinal tract [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR6">6</xref>]. The anti-cancer effects on rapidly dividing cells may shift the balance among functionally distinct cell types in the gastrointestinal epithelium and may cause changes in gastrointestinal physiology. The imbalance between absorption and secretion can lead to a large volume of fluid and electrolytes in the small bowel, which can overwhelm the absorptive capacity of the colon and result in CID [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. Recent study has shown changes in gut microbial composition (dysbiosis) in the pathogenesis of CID [<xref ref-type="bibr" rid="CR7">7</xref>]. The relative abundances of <italic>Lactobacillus </italic><italic>spp.</italic> and <italic>Bacteroides </italic><italic>spp.</italic> reduced in patient fecal samples after chemotherapy [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. However, there has been no comprehensive assessment of dysbiosis in patients with CID. With the development of metagenomic sequencing and analysis, there is a growing demand for such in-depth analyses of alterations in gut microbes and their causal associations with symptoms.</p><p id="Par36">In general, the pathogenesis of CID is poorly understood; however, based on the multidisciplinary literature review, adequate and appropriate use of loperamide is recommended for cancer patients suffering from gastrointestinal side effects [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. While loperamide remains a first-line therapeutic option for acute diarrhea management, its clinical application is constrained by limited high-quality evidence guiding optimal dosing strategies [<xref ref-type="bibr" rid="CR1">1</xref>]. Current guidelines advise against exceeding 16&#x000a0;mg daily due to diminishing therapeutic returns and recommend transitioning to alternative interventions if symptoms persist beyond 48&#x000a0;h [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. This cautious approach is necessitated by loperamide&#x02019;s dose-dependent opioid-like adverse effects, including central nervous system depression and respiratory depression [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. Other agents used for treating CID include octreotide and proteolytic enzymes; however, the underlying therapeutic mechanisms are not clearly understood [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. Alternatively, numerous probiotic organisms are known to modulate the severity of intestinal inflammation by altering the composition, metabolism, and functional properties of indigenous gut microbiota [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>], and many have been examined for the prevention and treatment of gastrointestinal conditions [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. These studies include randomized trials demonstrating that probiotic supplementation with <italic>Lactobacillus </italic><italic>spp. </italic>or <italic>Bifidobacterium </italic><italic>spp.</italic> can reduce the frequency of severe diarrhea and abdominal discomfort related to chemotherapy or radiotherapy without intolerable side effects [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. Nevertheless, the use of probiotics for preventing CID is also controversial because this strategy increases the risk of severe infections among immunocompromised patients [<xref ref-type="bibr" rid="CR2">2</xref>]. Considering these uncertainties, innovative approaches that target other steps in the pathophysiology of CID are urgently required. Therefore, we conducted a detailed evaluation of CID-related dysbiosis in humans and mice and tested several probiotic treatment protocols in the mice models to identify potentially effective therapies. This study broadens the knowledge about gut microbes in patients with CID and provides new insights into therapeutic strategies.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Participant recruitment and sample collection</title><p id="Par37">Patients hospitalized at oncology department in Nanfang hospital (the first affiliated hospital of Southern medical university, China) who met the inclusion and exclusion criteria were recruited in this research. The inclusion criteria were as follows: (1) age from 18 to 80&#x000a0;years; (2) pathologically diagnosed with gastrointestinal tumors; (3) undergoing chemotherapy (irinotecan, fluorouracil analog or the combination chemotherapy). The exclusion criteria were as follows: (1) received antibiotic drugs/endoscopy examination/radiation within 1&#x000a0;month; (2) received surgery within 3&#x000a0;months. For patients with cancer, pre-chemotherapy and post-chemotherapy samples were collected before the initiation or 12&#x000a0;h after the accomplishment of chemical regimen, respectively. All samples were storage at&#x02009;&#x02212;&#x02009;80&#x02103;. Human participants study protocol was approved by Ethics Committee of Southern Medical University Nanfang Hospital (NFEC-2020&#x02013;269).</p></sec><sec id="Sec4"><title>Animal models</title><p id="Par38">Six to eight weeks male BALB/c and C57BL/6 mice were obtained from Experimental animal center of Southern Medical University. All mice were housed in SPF condition with no more than 5 mice per cage. A total of 10 mice per experimental group were included in this study, based on pilot data indicating an effect size (<italic>d</italic>&#x02009;=&#x02009;1.5, <italic>&#x003b1;</italic>&#x02009;=&#x02009;0.05, power&#x02009;=&#x02009;0.8) with G Power 3.1-calculated minimum <italic>n</italic>&#x02009;=&#x02009;9 per group and ethical compliance (reduction: G Power 3.1-calcul of group size). Animal experiments were carried out after 7&#x000a0;days of acclimation. For tumor bearing, BALB/c mice were inoculated orthotopically at the surface of the cecum with CT26 tumor cells (1&#x02009;&#x000d7;&#x02009;10<sup>6</sup>) in 0.04&#x000a0;mL of PBS for tumor development. The animals were assigned into different groups using an Excel-based randomization software performing stratified randomization based upon their body weights 11&#x000a0;days after inoculation for further research. For safety assessment of <italic>hk-B.&#x000a0;f</italic>, C57BL/6 mice were orally administrated with 200 &#x003bc;L <italic>hk-B.&#x000a0;f</italic>-AF647 or DIBO-AF647. For CID modeling, mice gently restrained using a tunnel device to minimize stress. BALB/c mice were intraperitoneally injected with 5-FU (50&#x000a0;mg/kg/day) or CPT-11 (60&#x000a0;mg/kg/day) for 5&#x000a0;days according to previous articles [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Detailed modeling methods and grouping information are respectively shown in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>, Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>, Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>, Additional file 2: Fig. S4, and Additional file 2: Fig. S5. Probiotic efficacy was assessed in 5-FU- or CPT-11-induced CID murine models using primary (diarrhea severity) and secondary endpoints (body weight change, intestinal permeability). Treatment administration and outcome assessments were performed by separate investigators. Animal study protocols were approved by the Institutional Animal Care and Use Committee of Southern Medical University (K2021035).</p></sec><sec id="Sec5"><title>Bacteria strains</title><p id="Par39"><italic>Bacteroides fragilis</italic> (<italic>B.&#x000a0;f</italic>) strain ZY-312 and heat-killed <italic>B.&#x000a0;f</italic> (<italic>hk-B.&#x000a0;f</italic>) were obtained from ZYBio Co., Ltd. (Guangzhou, China). Bacteria were cultured in sterile tubes containing 10&#x000a0;ml of tryptone soy broth supplemented with 5% fetal bovine serum and incubated anaerobically at 37&#x000a0;&#x000b0;C. <italic>hk-B.&#x000a0;f</italic> was the inactivation status of living <italic>B.f</italic> through thermal inactivation (80&#x000a0;&#x000b0;C for 30&#x000a0;min). Triple probiotics formulation (<italic>PB3</italic>), consisted of <italic>Bifidobacterium longum</italic>, <italic>Lactobacillus acidophilus</italic>, and <italic>Streptococcus faecalis</italic>, was obtained from Sinepharm Co., Ltd. (Shanghai, China).</p></sec><sec id="Sec95"><title>Cell culture, cell transfection, and inhibitor administration</title><p id="Par40">Rat small intestinal crypt epithelial cells IEC-6 were cultured in Dulbecco&#x02019;s modified Eagle&#x02019;s medium (DMEM) supplemented with 10% fetal bovine serum (FBS) in 5% CO<sub>2</sub> at 37&#x02103;. IEC-6 cells underwent siRNA-mediated FAS or BCL2 knockdown using Lipofectamine 3000 (Tsingke Biotech) per manufacturer protocols. Post-transfection (6&#x000a0;h), cells were maintained in DMEM/10% FBS for 48&#x000a0;h prior to 5-FU (5&#x000a0;&#x003bc;M, 24&#x000a0;h) and <italic>hk-B.f</italic> (1&#x02009;&#x000d7;&#x02009;10<sup>8</sup>&#x000a0;CFU/mL, 24&#x000a0;h) or PBS treatment (24&#x000a0;h). For BCL2, the siRNA target sequence was 5&#x02032;&#x02013;3&#x02032;: AAGTTCGGTGGGGTCATGTGT. For FAS, the siRNA target sequence was 5&#x02032;&#x02013;3&#x02032;: GCUAUUGUGGACGGAGGUATT. For caspase inhibition, cells were pre-treated with Z-VAD-FMK (50&#x000a0;&#x003bc;M, Selleck 187,389&#x02013;52-2) for 6&#x000a0;h before 5-FU/<italic>hk-B.&#x000a0;f</italic> exposure.</p></sec><sec id="Sec85"><title>Mouse intestinal organoid culture</title><p id="Par41">Intestinal organoids were isolated and cultured in vitro using IntestiCult&#x02122; Organoid Growth Medium (06005, STEMCELL) following the manufacturer&#x02019;s instructions. Approximately 500 crypts were embedded in 50 &#x003bc;L Matrigel (356,231, Corning) per well of a 24-well plate and submerged in IntestiCult&#x02122; Organoid Growth Medium with included supplements. Organoids were then subcultured every 6&#x02013;7&#x000a0;days at 37&#x000a0;&#x02103;&#x000a0;in a 5% CO<sub>2&#x000a0;</sub> incubator with a 1:4 splitting ratio.</p></sec><sec id="Sec6"><title>Metagenomic sequencing</title><p id="Par42">High-quality metagenomic sequencing was conducted on 60 paired fecal samples (pre-/post-chemotherapy, <italic>n</italic>&#x02009;=&#x02009;30 patients) using standardized protocols. DNA extraction was performed with the MagPure Stool DNA KF Kit B (Magen, China): 200&#x000a0;mg fecal samples were transferred to sterile tubes containing grinding beads, homogenized with 1&#x000a0;mL Buffer ATL/PVP-10 using a grinding machine (Shanghai Jingxin Tech) at 65&#x000a0;&#x000b0;C for 20&#x000a0;min. The homogenate was centrifuged at 14000&#x02009;&#x000d7;&#x02009;<italic>g</italic> (5&#x000a0;min, Eppendorf), and the supernatant was transferred to a new tube. After adding 0.6&#x000a0;mL Buffer PCI and vortexing (15&#x000a0;s), the mixture was centrifuged at 18213&#x02009;&#x000d7;&#x02009;<italic>g</italic> (10&#x000a0;min). The supernatant was transferred to a deep-well plate containing 600 &#x003bc;L magnetic bead binding solution (20 &#x003bc;L Proteinase K&#x02009;+&#x02009;5 &#x003bc;L RNase A). Sequential washes (700 &#x003bc;L Wash 1, 700 &#x003bc;L Wash 2, 700 &#x003bc;L Wash 3) and elution (100 &#x003bc;L Elution Buffer) were performed on the KingFisher Flex system (Thermo Fisher). Purified DNA was stored at&#x02009;&#x02212;&#x02009;80&#x000a0;&#x000b0;C.</p><p id="Par43">Libraries were constructed from 200&#x000a0;ng DNA using the BGI Optimal DNA Library Prep Kit (BGI, China), involving fragmentation, single-stranded circularization, and rolling circle amplification to generate DNA nanoballs (DNBs). Sequencing was performed on the DNBSEQ-T7 platform (PE150, BGI) with DNB nanoarray loading. Raw data were processed through SOAPnuke v2.2.1 for quality trimming [<xref ref-type="bibr" rid="CR20">20</xref>], followed by host read removal (SOAP2 alignment to hg38) [<xref ref-type="bibr" rid="CR21">21</xref>]. High-quality reads were assembled de novo using MEGAHIT (k-mer 21&#x02013;121) [<xref ref-type="bibr" rid="CR22">22</xref>], retaining contigs&#x02009;&#x02265;&#x02009;300&#x000a0;bp for MetaGeneMark gene prediction [<xref ref-type="bibr" rid="CR23">23</xref>]. Non-redundant genes were filtered via CD-HIT (95% identity, 90% coverage) [<xref ref-type="bibr" rid="CR24">24</xref>], with taxonomic annotation performed using Kraken2 (LCA algorithm) [<xref ref-type="bibr" rid="CR25">25</xref>] against the NCBI NT sub-database k2_pluspf_16gb_20240112.</p></sec><sec id="Sec7"><title>RNA sequencing</title><p id="Par44">Total RNA from mice ilea was extracted using Trizol. In order to obtain mRNA, the extracted total RNA was purified with OligodT and DNA probes in order to eliminate the impact of nucleic acids as previously described [<xref ref-type="bibr" rid="CR26">26</xref>]. The mRNA was then reverse transcribed into cDNA. PCR amplification system was established with a mixture of A-Tailing Mix, RNA Index Adapters, and the cDNA. An Agilent 2100 Bioanalyzer (Thermo Fisher Scientific) and the StepOnePlus Real-Time PCR System (ABI, Foster City, CA, USA) were adapted for assessing the quality of the constructed libraries. The high-throughput sequencing was accomplished with Illumina HiSeq4000 platform (Illumina San Diego, CA, USA) by the Beijing Genomics Institute (BGI, Shenzhen, China) on the basis of the high-quality libraries. The clean reads were obtained after filtering the low-quality or contaminated raw reads. The reads were then queried against the target genome sequences (GCF_000001405.37_GRCh38.p11) using Bowtie2. Finally, the gene expression levels were assessed with RSEM (BGI).</p></sec><sec id="Sec75"><title>Diarrhea measurement</title><p id="Par45">Diarrhea score and fecal water content were measured daily for evaluating diarrhea degree of mice during treatment. Diarrhea score/grading was determined based on previous scoring standard [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. Fecal consistency was classified based on the following visual grading scale: (1) score&#x02009;=&#x02009;1, formed, stool maintains its shape, brown; (2) score&#x02009;=&#x02009;2, semi-formed or soft, does not pour, yellow; and (3) score&#x02009;=&#x02009;3, liquid, pours more easily. Fecal water content was determined by the equation: 1&#x02009;&#x02212;&#x02009;(dried solid content)/(total fecal content).</p></sec><sec id="Sec65"><title>Preparation of fluorescently Labeled <italic>hk-B.&#x000a0;f</italic></title><p id="Par46"><italic>B.&#x000a0;f</italic> was cultured for 65&#x000a0;h at 37&#x000a0;&#x000b0;C under anaerobic conditions (80% N<sub>2</sub>, 10% H<sub>2</sub>, 10% CO<sub>2</sub>) in an anaerobic glove box in basal peptone-yeast broth with GalNAz at a final concentration of 100&#x000a0;&#x003bc;M. Bacterium were spun down and washed three times in 1&#x02009;&#x000d7;&#x02009;PBS supplemented with 1% bovine serum albumin (BSA) when the OD600 value ranged from 0.7 to 1.4. The bacteria pellet was resuspended in 10&#x000a0;ml PBS supplemented with 1% BSA and 20&#x000a0;mM DIBO-AF647 (100 &#x003bc;L per vial) and each vial of the bacterium suspension was kept separately. Incubate the resuspension in a shaker and protected from light for 5&#x000a0;h. Centrifuge the resuspension with 1&#x02009;&#x000d7;&#x02009;PBS containing 3% BSA at 13000&#x000a0;rpm for 2&#x000a0;min, remove the supernatant, wash for five times. Resuspend the bacteria with 500 &#x003bc;L of 1&#x02009;&#x000d7;&#x02009;PBS containing 1% BSA, inactivated by thermal inactivation (80&#x000a0;&#x000b0;C for 30&#x000a0;min), cooled and centrifuged at 13000&#x000a0;rpm for 2&#x000a0;min, remove the supernatant, add 300 &#x003bc;L of 30% glycerol broth solution, and store in a freezer set to maintain&#x02009;&#x02212;&#x02009;20&#x000a0;&#x000b0;C.</p></sec><sec id="Sec615"><title>Optical imaging</title><p id="Par47">Thirty-nine C57BL/6 mice were randomly divided into three groups: blank control group (3 mice), test group (18 mice), and positive control group (18 mice). The test group and positive control group were randomly divided into six groups (3&#x000a0;h, 6&#x000a0;h, 12&#x000a0;h, 24&#x000a0;h, 48&#x000a0;h, and 60&#x000a0;h) with three mice coded sequentially in each group. The mice in the test group were given fluorescently labeled <italic>hk-B.&#x000a0;f</italic> by gavage, while the mice in the positive control group were given positive dye DIBO-AF647 by gavage, and the mice in the blank group were given PBS. Fluorescence intensity and distribution were measured at 3&#x000a0;h, 6&#x000a0;h, 12&#x000a0;h, 24&#x000a0;h, 48&#x000a0;h, and 60&#x000a0;h after gavage of the test interventions in mice. The fluorescence signals were detected by IVIS imaging system (PerkinElmer).</p></sec><sec id="Sec625"><title>Intestinal permeability analysis</title><p id="Par48">Intestinal permeability was evaluated with fluorescein isothiocyanate (FITC)-Dextran 4000 (78331, Sigma-Aldrich) as previously described [<xref ref-type="bibr" rid="CR29">29</xref>]. Briefly, fasting mice were administered of FITC-Dextran 4000 (600&#x000a0;mg/kg) by oral gavage. Four hours after gavage, fluorescence intensity of FITC-Dextran 4000 in plasm was detected.</p></sec><sec id="Sec695"><title>Antibodies</title><p id="Par49">Primary antibodies against GAPDH (60004&#x02013;1, Proteintech), Caspase3 (14220T, CST), Cleaved Caspase3 (9664T, CST), Occludin (91131S, CST), ZO-1 (402200, Invitrogen), Bax (60267&#x02013;1, Proteintech), and BCL2 (ab32124, Abcam) were used in this article.</p></sec><sec id="Sec8"><title>Non-targeted metabolomics analysis</title><p id="Par50">Six blank culture medium and six <italic>B.&#x000a0;f</italic> culture supernatant samples were collected. Samples were thawed on ice and vortexed. The extract containing the internal standard was added to the samples, and the supernatants were obtained by centrifugation (12000 r/min for 10&#x000a0;min at 4&#x000b0; C). Then sample supernatants were placed at&#x02009;&#x02212;&#x02009;20&#x000a0;&#x000b0;C for 30&#x000a0;min. Next, the supernatants were obtained by centrifugation (12000 r/min for 3&#x000a0;min at 4&#x000b0; C) for LC&#x02013;MS analysis. All samples were collected by the LC&#x02013;MS system according to machine instructions. UPLC column: Waters ACQUITY UPLC HSS T3 C18 (1.8&#x000a0;&#x003bc;m, 2.1&#x000a0;mm*100&#x000a0;mm). Then, column temperature, 40&#x000b0; C; flow rate, 0.4&#x000a0;mL/min; injection volume, 2 &#x003bc;L; solvent system containing water (0.1% formic acid) and acetonitrile (0.1% formic acid). The original data file acquired by LC&#x02013;MS was converted into mzML format by ProteoWizard software. Peak extraction, peak alignment, and retention time correction were respectively performed by the XCMS program. The &#x0201c;SVR&#x0201d; method was used to correct the peak area and filter data. After that, metabolic identification information was obtained by searching the laboratory&#x02019;s self-built database, integrated public database, AI database, and metDNA. The PCA scatter plot, volcano plot, and differential expression metabolites rank analysis were based on positive ion model data. Criteria for defining differential metabolites: VIP&#x02009;&#x02265;&#x02009;1, <italic>P</italic>-value&#x02009;&#x0003c;&#x02009;0.05 in Student&#x02019;s <italic>t</italic>-test and fold change&#x02009;&#x02265;&#x02009;2 or fold change&#x02009;&#x02264;&#x02009;0.5 between two groups.</p></sec><sec id="Sec9"><title>Extraction and purification of capsular polysaccharide TP2 from <italic>B. fragilis</italic> strain ZY-312</title><p id="Par51">Zwitterionic polysaccharide (ZPS) with an average relative molecular weight of 70&#x000a0;kDa from ZY-312 was isolated and purified according to previous published article [<xref ref-type="bibr" rid="CR30">30</xref>]. ZY312-derived capsular polysaccharide termed TP2. Polysaccharide TP2 was provided by Guangzhou Zhiyi Biotechnology Co., Ltd. (Guangzhou, China). The total sugar content of TP2 was 98%, the protein content was 1%, and the nucleic acid content was 0.5%. The repeating unit of TP2 consists of four monosaccharides: 2,4-dideoxy-4-amino-D-N-acetylfucose, D-N-acetylgalactosamine, D-galactopyranose, and D-galactofuranose with 4,6-pyruvate attached to the galactopyranose.</p></sec><sec id="Sec99"><title>Statistical analysis</title><p id="Par52">Normality was rigorously assessed using Shapiro&#x02013;Wilk tests (<italic>n</italic>&#x02009;&#x02264;&#x02009;50) and Kolmogorov&#x02013;Smirnov tests with Q-Q plots (<italic>n</italic>&#x02009;&#x0003e;&#x02009;50). Continuous variables were presented as mean&#x02009;&#x000b1;&#x02009;standard error of mean (SEM) for normally distributed data and median (interquartile range, IQR) for non-normal distributions. Two-group comparisons used independent/paired <italic>t</italic>-tests (parametric) or Mann&#x02013;Whitney <italic>U</italic>/Wilcoxon signed-rank tests (non-parametric), while multi-group analyses employed one-way ANOVA with Tukey&#x02019;s post hoc testing (parametric) or Kruskal&#x02013;Wallis with Dunn-Bonferroni correction (non-parametric). Correlation analysis was evaluated via Spearman&#x02019;s <italic>&#x003c1;</italic>. All statistical analyses incorporated appropriate adjustments for multiple comparisons using either Bonferroni correction or false discovery rate (FDR) adjustment and were conducted in SPSS version 19.0 software. Graphs were generated by GraphPad Prism 9.0 and R version 4.2.2 software. <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 indicates a significant difference.</p></sec><sec id="Sec10"><title>Supplementary methods are shown in additional file 1 [<xref ref-type="bibr" rid="CR31">31</xref>].</title></sec></sec><sec id="Sec11"><title>Results</title><sec id="Sec12"><title>Participant information</title><p id="Par53">The self-controlled study design is schematically presented in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>a. From 30 CID patients, paired pre-/post-chemotherapy fecal samples were collected (<italic>n</italic>&#x02009;=&#x02009;60 total), with microbiota composition compared through metagenomic sequencing (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>b). Clinico-demographic characteristics of this self-controlled cohort are detailed in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>c.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Bacterial diversity of the fecal microbiota associated with Pre- and Post-chemotherapy patients.&#x000a0;<bold>a</bold> Participant selection and specimen collection process.&#x000a0;<bold>b</bold> Study design and groups: 30 cancer patients with fecal samples both collected Pre- and Post-chemotherapy treatments (1). Samples were subjected to shotgun sequencing (2) and reads were mapped to reference databases (3) for sample-specific relative abundance calculation (4) and processed for nucleotide diversity and untargeted metabolomics (5).&#x000a0;<bold>c</bold> Demographic information of the involving patients.&#x000a0;<bold>d</bold> Fecal microbial alpha-diversity estimated by Chao1, Simpson, and Shannon index. <italic>p</italic> values were calculated by two-sided unpaired Wilcoxon test.&#x000a0;<bold>e</bold> Fecal microbial beta-diversity calculated under Bray-Curtis distance.&#x000a0;<bold>f</bold> Fecal microbial PCoA diagram calculated under Bray-Curtis distance.&#x000a0;<bold>g</bold> Relative abundance of the bacteria at the genus level.&#x000a0;<bold>h</bold> A Venn diagram displayed the overlaps between groups.&#x000a0;<bold>i</bold> The relative abundance of microbial genera including <italic>Bacteroides </italic><italic>spp.</italic>, <italic>Bifidobacterium </italic><italic>spp.</italic>, <italic>Lactobacillus </italic><italic>spp.</italic>, and <italic>Akkermansia </italic><italic>spp.</italic> between two groups. <italic>p</italic> values were calculated by two-sided paired Wilcoxon test.&#x000a0;<bold>j</bold> The relative abundance of microbial species <italic>Bacteroides fragilis</italic>, <italic>Bifidobacterium breve</italic>, <italic>Bifidobacterium longum</italic>, and <italic>Akkermansia muciniphila.&#x000a0;</italic><bold>k</bold>&#x000a0;Spearman&#x02019;s correlation between the relative abundance of <italic>Bacteroides fragilis</italic> at baseline and patient&#x02019;s diarrhea grade<italic>.&#x000a0;</italic><bold>d</bold>,<bold>e</bold>
<italic>p</italic>&#x000a0;values were calculated by two-sided unpaired Wilcoxon test<italic>.&#x000a0;</italic><bold>i</bold>,&#x000a0;<bold>j</bold>
<italic>p&#x000a0;</italic>values were calculated by two-sided paired Wilcoxon test.&#x000a0;Pre, pre-chemotherapy group; Post, post-chemotherapy group</p></caption><graphic xlink:href="12916_2025_4233_Fig1_HTML" id="MO4"/></fig></p></sec><sec id="Sec13"><title>Chemotherapy exposure alters gut microbiome composition</title><p id="Par54">Metagenomic profiling of paired fecal samples revealed genus-level taxonomic differences (Pre vs. Post) as shown in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>g. While fecal &#x003b1;-diversity (Chao1, Simpson, Shannon indices) remained stable (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>d), &#x003b2;-diversity based on Bray&#x02013;Curtis distances exhibited significant inter-group separation (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>e), visualized by PCoA diagram (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>f). A Venn diagram identified 328 core genera shared between groups, with 45 Pre-exclusive and 18 Post-exclusive taxa (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>h).</p><p id="Par55">We then identified these differentially abundant taxa. At the genus level, <italic>Bacteroides </italic><italic>spp.</italic> abundance was significantly reduced in Post group (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>i). Alternatively, neither <italic>Bifidobacterium </italic><italic>spp.</italic> nor <italic>Lactobacillus </italic><italic>spp.</italic> were significantly altered, despite their previously reported efficacy for improving CID. There was also no significant difference in the abundance of <italic>Akkermansia </italic><italic>spp.</italic> At the species level, there was a significant decrease in the abundance of <italic>B. fragilis</italic> (<italic>B.&#x000a0;f</italic>) in the Post group compared to the Pre group (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>j), whereas no substantial changes were observed in <italic>Bifidobacterium breve</italic>, <italic>Bifidobacterium longum</italic>, and <italic>Akkermansia muciniphila</italic>. The differential analysis with relative abundance is shown in Additional file 2: Fig. S1a, b. Correlation analysis (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>k) revealed that the abundance of <italic>B.f</italic> at baseline level had significantly negative correlation with patient&#x02019;s diarrhea grade (R&#x02009;=&#x02009;&#x02009;&#x02212;&#x02009;0.93, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001), which indicates that the relative abundance of <italic>B.&#x000a0;f</italic> at baseline may have protective effects in patients. Overall, these data suggest that community-level dysbiosis may contribute to CID. Further, <italic>Bacteroides </italic><italic>spp.</italic> and <italic>B.&#x000a0;f</italic> were identified as key taxa contributing to compositional alterations after chemotherapy.</p></sec><sec id="Sec14"><title>Functional analysis of fecal microbiota</title><p id="Par56">To examine the functional and metabolic changes in fecal microbial communities associated with chemotherapy, all clean reads from metagenomic sequencing were aligned to the suggested database for KEGG and GO enrichment analyses (Additional file 2: Fig. S1c). Samples from Pre group displayed a few differentially enriched KEGG metabolic pathway terms compared with samples from Post group. Several pathway terms related to amino acid metabolism, fatty acid biosynthesis, and lipopolysaccharide biosynthesis were overrepresented in the Pre group. These results indicate that chemotherapy markedly alters the metabolic properties of gut microbiota.</p></sec><sec id="Sec15"><title>Heat-killed <italic>B.&#x000a0;f</italic> improved 5-FU-induced CID</title><p id="Par57">Given the negative correlation between baseline <italic>B. f</italic> abundance and CID severity, we hypothesized that targeted <italic>B. f</italic> supplementation might mitigate CID. This mechanistic hypothesis was subsequently validated in preclinical murine models. Surprisingly, experiments comparing the efficacy of living <italic>B.&#x000a0;f</italic> to heat-killed <italic>B.&#x000a0;f</italic> (<italic>hk-B.&#x000a0;f</italic>) and a combination probiotic (<italic>PB3</italic>) revealed that <italic>hk-B.&#x000a0;f</italic> was most effective for restoring body weight loss and reducing diarrhea in 5-FU-induced mouse models of CID (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>a, b, c). Current clinical guidelines recommend LPM as first-line therapy for CID, yet explicitly contraindicate its use in bloody diarrhea&#x02014;conditions recapitulated in our 5-FU-induced murine CID model (occult blood in 20% of mice in pre-experiment). This paradox prompted our comparative analysis of LPM and various doses of <italic>hk-B.&#x000a0;f</italic> (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>a). Significantly decreased body weight and daily food intake (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>b, i) and increased intestinal permeability and fecal water content (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>c, f, h) were observed in mice stimulated with 5-FU, indicating that this model mice recapitulated the core features of CID. Different doses of <italic>hk-B.&#x000a0;f</italic> and a standard dose of LPM maintained normal intestinal permeability (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>c); however, <italic>hk-B.&#x000a0;f</italic> was more efficacious at reducing diarrhea grade. In both treatment groups, diarrhea grade fluctuated with time during treatment (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>d), and neither <italic>hk-B.&#x000a0;f</italic> nor LPM improved diarrhea from day 8 to day 10. However, the high dose of <italic>hk-B.&#x000a0;f</italic>, <italic>hk-B.&#x000a0;f(H)</italic>, significantly reduced the diarrhea score on days 11 and 12 (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>d). Moreover, <italic>hk-B.&#x000a0;f(H)</italic> significantly decreased the fecal water content on day 12 (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>h) and increased feed consumption on average per cage (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>i), while LPM failed to improve diarrhea in the 5-FU-induced CID model.<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>The effect of probiotics on 5-FU induced CID model in mice.&#x000a0;<bold>a</bold> Schematic diagram of the treatment schedule and timeline for CID model with 5-FU stimulation.&#x000a0;<bold>b</bold> Body weight change in different experimental groups with 5-FU stimulation. <italic>p</italic> values were calculated with one-way ANOVA test. <italic>n</italic>&#x02009;=&#x02009;10 mice for each experimental group.&#x000a0;<bold>c</bold> The distribution of diarrhea grade of mice recorded at day 9 (before sacrifice) with 5-FU stimulation. Significant importance was calculated with Kruskal-Wallis H test among groups. Between group differences were accomplished with Mann-Whitney <italic>U</italic> test. The asterisk represents significant difference compared to 5-FU group. <italic>n</italic>&#x02009;=&#x02009;10 for each group.&#x000a0;<bold>b</bold>,<bold> c</bold>
<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 indicates significant difference. *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001, ****<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001, ns, no significance.&#x000a0;<italic>B.&#x000a0;f</italic>, <italic>Bacteroides fragilis</italic>; <italic>hk-B.&#x000a0;f</italic>, heat-killed <italic>Bacteroides fragilis</italic>; <italic>PB3</italic>, triple probiotics combination of living <italic>Bifidobacterium longum</italic>, <italic>Lactobacillus acidophilus</italic> and <italic>Streptococcus faecalis</italic></p></caption><graphic xlink:href="12916_2025_4233_Fig2_HTML" id="MO1"/></fig><fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>The effect of different doses of <italic>hk-B. f</italic> on 5-FU stimulated CID model.&#x000a0;<bold>a</bold> Schematic diagram of the treatment schedule and timeline for CID model.&#x000a0;<bold>b</bold> Body weight change in different experimental groups (<italic>n</italic>&#x02009;=&#x02009;10 for each group).&#x000a0;<bold>c</bold> FITC-Dextran permeability in different experimental groups (<italic>n</italic>&#x02009;=&#x02009;10 for each group).&#x000a0;<bold>d</bold> The distribution of diarrhea grade of mice recorded from day 8 (end of modeling) to day 12 (end of experiment). Fecal consistency was classified based on the following visual grading scale: score&#x02009;=&#x02009;0, normal; score&#x02009;=&#x02009;1, soft feces or small black feces; score&#x02009;=&#x02009;2, muddy feces; and score&#x02009;=&#x02009;3, watery feces or mucous feces. Significant importance was calculated with Kruskal-Wallis H test among groups. Between groups differences were accomplished with Mann-Whitney <italic>U</italic> test. The asterisk represents significant difference compared to 5-FU group (<italic>n</italic>&#x02009;=&#x02009;10 for each group).&#x000a0;<bold>e&#x02013;h</bold> Fecal wet weight (<bold>e</bold>, <bold>g</bold>) and fecal water content (<bold>f</bold>, <bold>h</bold>) at day 8 or day 12. Fecal water content was determined by the following equation: 1&#x02009;&#x02212;&#x02009;(dried solid content)/(fecal wet weight)&#x02009;&#x000d7;&#x02009;100%.&#x000a0;<bold>i</bold> Daily food intake recorded every 4&#x000a0;days for each experimental group.&#x000a0;<bold>b</bold>,<bold> c</bold>,<bold> e&#x02013;i</bold> Significant importance was calculated with one-way ANOVA test. *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001, ****<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001, ns, no significance.&#x000a0;<italic>hk-B.&#x000a0;f</italic>, heat-killed <italic>Bacteroides fragilis</italic>; <italic>hk-B.&#x000a0;f</italic>(L), low-dose of <italic>hk-B.&#x000a0;f</italic>; <italic>hk-B.&#x000a0;f</italic>(M), medium-dose of <italic>hk-B.&#x000a0;f</italic>; <italic>hk-B.&#x000a0;f</italic>(H), high-dose of <italic>hk-B.&#x000a0;f</italic>; LPM, loperamide</p></caption><graphic xlink:href="12916_2025_4233_Fig3_HTML" id="MO2"/></fig></p><p id="Par58">We further performed 16S RNA sequencing of fecal samples from 5-FU-induced CID mice to explore whether different doses of <italic>hk-B.f</italic> alter mice intestinal microbiota composition. As shown in Additional file 2: Fig. S2a-c, low, medium, and high doses of <italic>hk-B.&#x000a0;f</italic> did not alter &#x003b1;-diversity or &#x003b2;-diversity. Overall, as indicated in Additional file 2: Fig. S2d, e, there is a difference between the two batches of differential analysis. <italic>hk-B.&#x000a0;f(H)</italic> significantly increased the relative abundance of <italic>Bacteroides </italic><italic>spp.</italic> in batch B (Additional file 2: Fig. S2d, e), which provides additional evidence for the therapeutic effect of <italic>Bacteroides </italic><italic>spp.</italic> on CID dysbiosis in mice.</p></sec><sec id="Sec16"><title>High dose of <italic>hk-B.&#x000a0;f</italic> improved ileal mitochondrial structure and function</title><p id="Par59">Next, we analyzed the effects of <italic>hk-B.&#x000a0;f</italic> supplementation on global gene expression and found that multiple pathways related to mitochondrial structure were enriched in the <italic>hk-B.&#x000a0;f(H)</italic> sample group (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>a). Further analysis demonstrated that genes encoding mitochondrial respiratory complex proteins (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>b) were upregulated in the ileum of <italic>hk-B.&#x000a0;f(H)-</italic>supplemented mice. Biochemical analysis of ileum tissue from 5-FU-induced CID model mice revealed a significant reduction in ATP concentration (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>d), whereas transmission electron microscopy (TEM) revealed a significant decline in mitochondrial number (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>c, e), and both these deficits were alleviated after <italic>hk-B.&#x000a0;f(H)</italic> supplementation. The overall area occupied by mitochondria was also significantly larger in the 5-FU-induced CID model group than the control and <italic>hk-B.&#x000a0;f(H)</italic> groups (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>c), suggesting that untreated CID is associated with mitochondrial swelling and dysfunction. Quantitative data analysis indicated that 5-FU-induced mitochondrial swelling which possibly disturbed proper function of mitochondria and can be ameliorated by <italic>hk-B.&#x000a0;f(H)</italic> (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>f). Furthermore, we performed quantitative evaluation for mitochondrial ultrastructural changes with methods in previous published articles [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. Based on these criteria, we identified healthy and damaged mitochondria with the use of individual images. The results exhibited significantly lower levels of grey scale unit in <italic>hk-B.&#x000a0;f(H)</italic> and control, which indicated healthier mitochondria (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>g). Overall, these results supported the prediction derived from gene expression data and illustrated that <italic>hk-B.&#x000a0;f(H)</italic> protected ileal mitochondria which were damaged by 5-FU.<fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>Ileal mitochondria destructions were ameliorated by the supplementation with high dose of <italic>hk-B.&#x000a0;f</italic>.&#x000a0;<bold>a</bold> Over-represented modules in GO enrichment shown in mice supplemented with high dose of <italic>hk-B.&#x000a0;f</italic> (<italic>n</italic>&#x02009;=&#x02009;3 for each group).&#x000a0;<bold>b</bold> A heatmap showing the median expression of genes from the respiratory chain process in the ilea of mice.&#x000a0;<bold>c</bold> Representative TEM images in ileal epithelial cells. Scale bars, 10&#x000a0;&#x003bc;m for the left image and 5&#x000a0;&#x003bc;m for the right image in each experimental group.&#x000a0;<bold>d</bold> ATP concentration extracted from ileal tissue (<italic>n</italic>&#x02009;=&#x02009;5 for each group).&#x000a0;<bold>e&#x02013;g</bold> Various metrics of mitochondria in the ileum of mice. <italic>n</italic>&#x02009;=&#x02009;5 mice for each group in mitochondrial count. <italic>n</italic>&#x02009;=&#x02009;100 mitochondria for each group in recording mitochondrial size and gray scale unit.&#x000a0;Between-group significant importance for <bold>d&#x02013;g</bold> were accomplished with Mann-Whitney <italic>U</italic> test. *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001, ****<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001, ns, no significance. <italic>hk-B.&#x000a0;f</italic>, heat-killed <italic>Bacteroides fragilis</italic>; <italic>hk-B.&#x000a0;f</italic>(H), high-dose of <italic>hk-B.&#x000a0;f</italic>; LPM, loperamide. TEM, transmission electron microscopy</p></caption><graphic xlink:href="12916_2025_4233_Fig4_HTML" id="MO5"/></fig></p></sec><sec id="Sec17"><title>Heat-killed <italic>B.&#x000a0;f</italic> protects against 5-FU-induced crypt damage and epithelial tight junction loss</title><p id="Par60">We next explored the molecular mechanisms of mitochondrial protection by <italic>hk-B.&#x000a0;f</italic> in the 5-FU-induced model of CID. Histological staining of ileal tissue from untreated model mice revealed substantial degeneration of mucosal integrity and crypt structure. Histological staining of ileal tissue from untreated model mice revealed substantial degeneration of mucosal integrity and crypt structure (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>b), and these injuries were partially mitigated by <italic>hk-B.&#x000a0;f</italic> and LPM without interfering with the antitumor effects of 5-FU (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>a). Alcian blue staining revealed a decline in the number of mucus-filled cells in the 5-FU group (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>c). When treated with <italic>hk-B.&#x000a0;f(H)</italic> or LPM, the number of mucus-filled cells significantly increased. Immunostaining also showed that the staining intensity of tight junction proteins ZO-1 and occludin were reduced and that the distributions of these proteins were aberrant and discontinuous in untreated model mice (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>d, e). <italic>hk-B.&#x000a0;f(M)</italic>, <italic>hk-B.&#x000a0;f(H)</italic>,and LPM restored ZO-1 localization to the apical regions, improved boundary continuity, and enhanced the staining intensities of ZO-1 and occludin. Consistent with immunostaining, western blot results confirmed that <italic>hk-B.&#x000a0;f(H)</italic> and LPM reduced the decline in occludin expression (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>f, h), although there were no effects on ZO-1 expression compared to untreated model mice (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>f, g).<fig id="Fig5"><label>Fig.&#x000a0;5</label><caption><p>The effect of different interventions on intestinal histological structure in tumor-bearing CID model.&#x000a0;<bold>a</bold> Representative tumor growth images for different experimental groups. Scale bars, 1&#x000a0;cm. Red arrows indicate tumor located on cecum.&#x000a0;<bold>b</bold> HE staining for ileal tissue in different experimental groups. Scale bars, 500&#x000a0;&#x003bc;m for&#x02009;&#x000d7;&#x02009;4 images, 200&#x000a0;&#x003bc;m for&#x02009;&#x000d7;&#x02009;20 images.&#x000a0;<bold>c</bold> Alcian blue staining for ileal tissue in different experimental groups. Scale bars, 200&#x000a0;&#x003bc;m.&#x000a0;<bold>d, e</bold> Immunofluorescence section for Occludin (green) or ZO-1 (green) with DAPI (blue) staining of ileum. Scale bars, 200&#x000a0;&#x003bc;m.&#x000a0;<bold>f&#x02013;h</bold> Western blot and quantification for the expression level of tight junction proteins in ileal tissue. Significant differences for quantification were calculated with one-way ANOVA test. *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001, ****<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001.&#x000a0;<bold>a&#x02013;f</bold> Images are representative of at least 5 mice per condition.&#x000a0;<bold>f</bold> Western blot analysis was repeated for at least 3 times.&#x000a0;<italic>hk-B.&#x000a0;f</italic>, heat-killed <italic>Bacteroides fragilis</italic>; <italic>hk-B.&#x000a0;f</italic>(L), low-dose of <italic>hk-B.&#x000a0;f</italic>; <italic>hk-B.&#x000a0;f</italic>(M), medium-dose of <italic>hk-B.&#x000a0;f</italic>; <italic>hk-B.&#x000a0;f</italic>(H), high-dose of <italic>hk-B.&#x000a0;f</italic>; LPM, loperamide</p></caption><graphic xlink:href="12916_2025_4233_Fig5_HTML" id="MO6"/></fig></p></sec><sec id="Sec18"><title>Heat-killed <italic>B.&#x000a0;f</italic> alleviates 5-FU-induced intestinal epithelial apoptosis by shifting the balance between anti-apoptotic BCL2 and proapoptotic BAX</title><p id="Par61">We then examined the molecular mechanisms for mitochondrial protection by <italic>B.&#x000a0;f.</italic> The number of TUNEL-positive (apoptotic) cells was significantly greater in tissues from the 5-FU model group than the control group, and most TUNEL-positive cells located in crypts (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>a). The epithelial cell apoptosis rate was reduced by <italic>hk-B.&#x000a0;f</italic> and LPM (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>a). Western blot analysis indicated that these treatments reduced the expression of the apoptosis effector cleaved caspase-3 (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>d, g). We further investigated the upstream mechanism of caspase-3-mediated apoptosis and found that the expression of anti-apoptotic BCL2 significantly reduced in the 5-FU group compared to the control group, and that this downregulation was partially reversed by <italic>hk-B.&#x000a0;f</italic> or LPM (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>b, d, e). Alternatively, expression of proapoptotic BAX was markedly enhanced by 5-FU exposure, and this effect was again reversed by <italic>hk-B.&#x000a0;f</italic> and LPM (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>c, d, f). No significant changes were detected in the levels of inflammatory cytokines among groups (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>h). These data demonstrated that <italic>hk-B.&#x000a0;f</italic> and LPM can ameliorate 5-FU-induced epithelial cell apoptosis by shifting the BCL2/BAX balance and thereby preventing activation of the mitochondrial apoptotic pathway.<fig id="Fig6"><label>Fig.&#x000a0;6</label><caption><p>The effect of different interventions on mitochondrial-apoptotic pathway.&#x000a0;<bold>a</bold> Tunel-staining (red) with DAPI (blue) for ileal tissue in different experimental groups. Scale bars, 200&#x000a0;&#x003bc;m. White arrows indicated Tunel-positive cells.&#x000a0;<bold>b, c</bold> Immunohistochemical sections for BCL2 or BAX staining of ileum. Scale bars, 200&#x000a0;&#x003bc;m.&#x000a0;<bold>d&#x02013;g</bold> Western blot and quantification for the expression level of mitochondrial-apoptotic proteins in ileal tissue. Significant differences for quantification were calculated with one-way ANOVA test. *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001, ****<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001.&#x000a0;<bold>h</bold> A heatmap displays the level of serous cytokines with ELISA assay. <italic>n</italic>&#x02009;=&#x02009;10 mice for each group. Data were normalized with log10.&#x000a0;<bold>a&#x02013;d</bold> Images are representative of at least 5 mice per condition.&#x000a0;<bold>d</bold> Western blot analysis was repeated for at least 3 times.&#x000a0;<italic>hk-B.&#x000a0;f</italic>, heat-killed <italic>Bacteroides fragilis</italic>; <italic>hk-B.&#x000a0;f</italic>(L), low-dose of <italic>hk-B.&#x000a0;f</italic>; <italic>hk-B.&#x000a0;f</italic>(M), medium-dose of <italic>hk-B.&#x000a0;f</italic>; <italic>hk-B.&#x000a0;f</italic>(H), high-dose of <italic>hk-B.&#x000a0;f</italic>; LPM, loperamide</p></caption><graphic xlink:href="12916_2025_4233_Fig6_HTML" id="MO7"/></fig></p></sec><sec id="Sec19"><title>Heat-killed B.f reversed 5-FU-stimulated apoptosis in in vitro epithelial barrier models</title><p id="Par62">We further tested these effects in an in vitro barrier model established with the rat epithelial cell line IEC-6. Consistent with tissue immunoblotting results, 5-FU induced cell apoptosis as measured by the CCK-8 assay and barrier function loss as evidenced by the TEER assay, whereas <italic>hk-B.&#x000a0;f</italic> treatment partially restored the proliferation rate and barrier integrity (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>a, b). In addition, Western blot analysis confirmed that 5-FU reduced BCL2, ZO-1, and occludin expression levels and that <italic>hk-B.&#x000a0;f</italic> reversed these effects (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>c). Consistent with tissue studies, 5-FU treatment alone increased BAX and cleaved caspase-3 expression levels, and these effects were reversed by <italic>hk-B.&#x000a0;f</italic>. Furthermore, flow cytometry analysis of Annexin V-FITC/PI-stained cells showed that <italic>hk-B.&#x000a0;f</italic> co-treatment reduced the rate of apoptosis compared to 5-FU treatment alone (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>d). These results were further confirmed by scanning electron microscopy (SEM). As shown in Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>e, after stimulation with 5-FU, IEC-6 cells exhibited swelling, nuclear fragmentation, and membrane rupture, and that all these signs were mitigated by<italic> hk-B.&#x000a0;f.</italic><fig id="Fig7"><label>Fig.&#x000a0;7</label><caption><p><italic>hk-B.&#x000a0;f</italic> improves 5-FU induced injury both in IEC-6 cell line and small intestinal organoids.&#x000a0;<bold>a</bold> Proliferation curve detected by CCK-8 assay for IEC-6 cells.&#x000a0;<bold>b</bold> TEER for IEC-6 cells. Black arrow indicates the time of 5-FU stimulation.&#x000a0;<bold>c</bold> Western blot analysis for the expression of tight junction proteins and apoptotic proteins in IEC-6 cells.&#x000a0;<bold>d</bold> Apoptosis rate of IEC-6 cells with different interventions detected by flow cytometry analysis.&#x000a0;<bold>e</bold> Representative images of SEM observation for IEC-6 cells under different conditions. Scale bars, 50&#x000a0;&#x003bc;m.&#x000a0;<bold>f</bold> Representative images of optic microscopy (left panel) and TEM (right panel) observations for small intestinal organoids with different interventions. Scale bars, 400&#x000a0;&#x003bc;m for optic microscope images, 2&#x000a0;&#x003bc;m for TEM images.&#x000a0;<bold>g</bold>, <bold>h</bold> Statistical analysis for cross-section area and budding count of organoids. Between-group differences were calculated with Mann-Whitney <italic>U</italic> test.&#x000a0;<bold>a&#x02013;f</bold> Experiments were repeated for at least 3 times.&#x000a0;<bold>a</bold>,<bold> b</bold>,<bold> d</bold>,<bold> g</bold>,<bold> h</bold> *indicates significant difference. *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001, ****<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001.&#x000a0;<italic>hk-B.&#x000a0;f</italic>, heat-killed <italic>Bacteroides fragilis</italic>; TEER, trans-epithelial elective resistance; SEM, scanning electron microscopy; TEM, transmission electron microscopy</p></caption><graphic xlink:href="12916_2025_4233_Fig7_HTML" id="MO8"/></fig></p><p id="Par63">Small intestinal organoids extracted from the small intestines of C57BL/6 mice grew and developed normally (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>f), while those stimulated by 5-FU were severely injured, with quantitatively decreased budding count and overall area (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>g, h). <italic>hk-B.&#x000a0;f</italic> supplementation improved organoid growth and development as evidenced by significantly higher budding count and larger organoid surface area.</p></sec><sec id="Sec20"><title>Silencing of BCL2 and caspase-3 interferes with the therapeutic effects of <italic>hk-B.&#x000a0;f</italic></title><p id="Par64">To confirm that <italic>hk-B.&#x000a0;f</italic> ameliorates 5-FU-induced gut epithelial damage by reducing mitochondrial apoptotic pathway activity, rescue experiments were conducted. As expected, <italic>hk-B.&#x000a0;f</italic> failed to reduce 5-FU-induced apoptosis when the downstream effector cleaved caspase-3 was pharmacologically inhibited by Z-VAD-FMK or the upstream anti-apoptosis protein BCL2 was silenced by a targeted siRNA (Additional file 2: Fig. S3a&#x02013;f). In contrast, siRNA-mediated knockdown of FAS, which acts on the upstream factor in the extrinsic apoptosis pathway, reduced baseline apoptosis rate following 5-FU treatment (Additional file 2: Fig. S3g, h, i) but did not interfere with the ameliorative effects of <italic>hk-B.&#x000a0;f</italic> on cell proliferation and apoptosis. Western blot analyses (Additional file 2: Fig. S3j) also confirmed that <italic>hk-B.&#x000a0;f</italic> restored the BCL2/BAX balance and prevented cleaved caspase-3 activation in 5-FU-treated cells.</p></sec><sec id="Sec21"><title><italic>B.&#x000a0;f</italic>-derived succinic acid weakens the probiotic effect of capsule polysaccharides</title><p id="Par65">Previous results showed that <italic>hk-B.&#x000a0;f</italic> exerted stronger effects than the living state. Heat-inactivation partly preserves cellular components and denatures metabolites. Here, we supposed that <italic>B.&#x000a0;f</italic>-derived metabolites played a key role in the discrepant therapeutic effect between <italic>hk-B.&#x000a0;f</italic> and live <italic>B.&#x000a0;f.</italic> Live <italic>B.&#x000a0;f</italic>, <italic>hk-B.&#x000a0;f</italic>, and <italic>B.&#x000a0;f</italic>-derived culture supernatant were administered to CID model mice (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>a&#x02013;f). Unexpectedly, we found that the supernatant aggravates weight loss (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>b) and pathological injury of mice ileum (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>f). To further probe the detrimental substances secreted by live <italic>B.&#x000a0;f</italic>, we performed non-targeted metabolomics analysis on the culture supernatant from the blank medium and live <italic>B.&#x000a0;f</italic> culture supernatants. Volcano plots and principal component analysis showed that these supernatants exhibited different metabolite profiles (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>g, h). We found that, succinic acid (SA) and propionic acid (PA) markedly enriched in live <italic>B.&#x000a0;f</italic> supernatant and represented the two largest fold changes in organic acid profile (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>i). Collectively, these results indicated that SA or PA may participate in CID progression.<fig id="Fig8"><label>Fig.&#x000a0;8</label><caption><p>The effect of <italic>B.&#x000a0;f</italic> metabolites and cellular component TP2 on 5-FU stimulated CID model.&#x000a0;<bold>a</bold>,<bold>&#x000a0;i</bold> Schematic diagram of the experimental grouping and timeline for CID model.&#x000a0;<bold>b</bold>,<bold>&#x000a0;k</bold> Body weight change in different experimental groups (<italic>n</italic>&#x02009;=&#x02009;10 for each group). The asterisk represents significant difference compared to 5-FU group.&#x000a0;<bold>c</bold>,<bold> l</bold> The distribution of diarrhea grade of mice recorded at day 12 (end of experiment). Significant importance was calculated with Kruskal-Wallis H test among groups. Between groups differences were accomplished with Mann-Whitney <italic>U</italic> test. The asterisk represents significant difference compared to 5-FU group (<italic>n</italic>&#x02009;=&#x02009;10 for each group).&#x000a0;<bold>d</bold>,<bold> m</bold> Fecal water content at day 12.&#x000a0;<bold>e</bold>,<bold> n</bold> FITC-Dextran permeability in different experimental groups (<italic>n</italic>&#x02009;=&#x02009;10 for each group).&#x000a0;<bold>f</bold>,<bold> o</bold> HE staining for ileal tissue in different experimental groups. Scale bars, 500&#x000a0;&#x003bc;m for&#x02009;&#x000d7;&#x02009;4 images, 100&#x000a0;&#x003bc;m for&#x02009;&#x000d7;&#x02009;20 images.&#x000a0;<bold>g</bold> Volcano plot of non-targeted metabolomics analysis (<italic>B.f</italic> supernatant group vs blank culture medium group, <italic>n</italic>&#x02009;=&#x02009;6 for each group).&#x000a0;<bold>h</bold> Scatter plots of OPLSDA of non-targeted metabolomics analysis.&#x000a0;<bold>i</bold> The heatmap and fold change (FC) value ranking of differently expressed metabolites in organic acid profile.&#x000a0;<italic>B.&#x000a0;f</italic>, <italic>Bacteroides fragilis</italic>; <italic>hk-B.&#x000a0;f</italic>, heat-killed <italic>Bacteroides fragilis</italic>; TP2, capsular polysaccharides isolated and purified from <italic>Bacteroides fragilis</italic> strain ZY-312; PA, propionic acid; SA, succinic acid.&#x000a0;*Indicates significant difference. *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001, ****<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001</p></caption><graphic xlink:href="12916_2025_4233_Fig8_HTML" id="MO3"/></fig></p><p id="Par66">The most studied of the <italic>B.&#x000a0;f</italic> capsular polysaccharide is polysaccharide A (PSA), which is considered as one of the sources of probiotic effects produced by <italic>B.&#x000a0;f</italic> [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. We isolated and purified capsular PS from <italic>B.&#x000a0;f</italic> strain ZY-312 and entitled TP2 [<xref ref-type="bibr" rid="CR30">30</xref>]. TP2, PA, and SA were next orally administered to CID mice (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>j&#x02013;o). Compared with CID group, body weight, diarrhea severity, intestinal permeability, and pathological injury of mice ileum were ameliorated by the administration of TP2 while aggravated by SA rather than PA. Collectively, this result indicates that <italic>B.&#x000a0;f</italic>-secreted SA weakens the probiotic effect of TP2 on mice with CID, which may explains the discrepant therapeutic effect between <italic>hk-B.&#x000a0;f</italic> and live<italic> B.&#x000a0;f.</italic></p></sec><sec id="Sec22"><title>Heat-killed <italic>B.&#x000a0;f</italic> improved CPT-11-induced CID</title><p id="Par67">Experiments comparing the efficacy of living <italic>B.&#x000a0;f</italic> to <italic>hk-B.&#x000a0;f</italic> and <italic>PB3</italic> revealed that <italic>hk-B.&#x000a0;f</italic> was the most effective for restoring body weight loss and reducing diarrhea in CPT-11-induced mouse model of CID (Additional file 2: Fig. S4a-c). The CPT-11-induced CID model was also established to assess the relative efficacy of LPM and different doses of <italic>hk-B.&#x000a0;f</italic> (Additional file 2: Fig. S5). Although neither treatment increased body weight, average feed consumption, or fecal wet weight (Additional file 2: Fig. S5b, S5d&#x02013;h), both <italic>hk-B.&#x000a0;f(M)</italic> and <italic>hk-B.&#x000a0;f(H)</italic> were effective for improving diarrhea (Additional file 2: Fig. S5c), whereas LPM failed to improve diarrhea compared to the untreated model group. The fecal water content was significantly higher in the LPM group on day 12 (Additional file 2: Fig. S5c, g). To summarize, <italic>hk-B.&#x000a0;f(H)</italic> was proved to be effective against CID induced by CPT-11, whereas LPM was ineffective.</p></sec><sec id="Sec23"><title>Safety evaluation of <italic>hk-B.&#x000a0;f</italic></title><p id="Par68">We investigated the safety of <italic>hk-B.&#x000a0;f</italic> by monitoring the activity of fluorescently labeled specimens throughout the gastrointestinal tract post-dose. The fluorescence signals from Alexa Fluro 647 <italic>hk-B.&#x000a0;f</italic> (<italic>hk-B.&#x000a0;f</italic>-AF647) and DIBO-AF647 dye group were similar, reaching peak intensities at 3&#x000a0;h post-dose and gradually decreasing thereafter (Additional file 2: Fig. S6a, b), although <italic>hk-B.&#x000a0;f</italic>-AF647 demonstrated stronger retention in vivo over time. However, at 60&#x000a0;h, DIBO-AF647 fluorescence increased abruptly, possibly because of coprophagia (Additional file 2: Fig. S6c, d). Quantitative analysis demonstrated that fluorescence intensities in extraintestinal organs (heart, liver, kidney, spleen, and lung) of <italic>hk-B.&#x000a0;f</italic>-AF647 group showed no significant differences compared to DIBO-AF647 group. Therefore, we conclude that <italic>hk-B.&#x000a0;f</italic> exhibits no evidence of ectopic colonization in extraintestinal tissues (Additional file 2: Fig. S6e). The distribution of <italic>hk-B.&#x000a0;f</italic>-AF647 in the mouse GI tract is shown in Additional file 2: Fig. S7&#x02013;S9. A strong fluorescence signal was observed in the stomach at 3&#x000a0;h post-dose, which decreased gradually until it was undetectable at 24&#x000a0;h post-dose (Additional file 2: Fig. S7b). <italic>hk-B.&#x000a0;f</italic>-AF647 fluorescence signal began to appear in the ileum at 3&#x000a0;h post-dose and gradually increased, peaking at 6&#x000a0;h post-dose, and then gradually decreased until undetectable after 48&#x000a0;h post-dose. Thus, labeled <italic>hk-B.&#x000a0;f</italic> stayed in the ileum for approximately 48&#x000a0;h (Additional file 2: Fig. S8b). The distribution of <italic>hk-B.&#x000a0;f</italic>-AF647 in the mouse colon is shown in Additional file 2: Fig. S9b. <italic>hk-B.&#x000a0;f</italic>-AF647 fluorescence signal was observed in the colon at 6&#x000a0;h post-dose. The signals were weak at other time points. To summarize, <italic>hk-B.&#x000a0;f</italic> transiently stayed in the gastrointestinal tract (mainly in the upper digestive tract). In the meantime, <italic>hk-B.&#x000a0;f</italic> did not colonize extra-gastrointestinal organs.</p></sec></sec><sec id="Sec24"><title>Discussion</title><p id="Par69">This study provides the first comprehensive analysis of the microbial community structure in patients with cancer undergoing chemotherapy using metagenomic sequencing. A comparison of paired fecal samples before and after chemotherapy revealed significantly reduced &#x003b2;-diversity following chemotherapy, and <italic>Bacteroides </italic><italic>spp.</italic>, especially <italic>B.&#x000a0;f</italic>, were identified as major contributors to this alteration.</p><p id="Par70">Previous research has demonstrated reduced <italic>Lactobacillus </italic><italic>spp.</italic> and <italic>Bacteroides </italic><italic>spp.</italic> abundance in patients receiving chemotherapy compared with healthy controls [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. However, in our self-controlled pairwise study of the microbial composition before and after chemotherapy, we found no substantial differences in <italic>Bifidobacterium </italic><italic>spp.</italic> or <italic>Lactobacillus </italic><italic>spp.</italic> abundance, despite clinical trials reporting the efficacy of <italic>Bifidobacterium</italic> in preventing CID [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. We detected substantial differences in the abundance of <italic>Bacteroides </italic><italic>spp.</italic> Based on these findings, we compared the therapeutic efficacy of bacterial supplementation against 5-FU- and CPT-11-induced CID in mice and found that heat-killed <italic>B.&#x000a0;f</italic> was superior to living <italic>B.&#x000a0;f</italic> and <italic>PB3</italic>. Moreover, <italic>hk</italic>-<italic>B.&#x000a0;f</italic> was generally superior to LPM, which is the recommended first-line treatment for CID. In vivo fluorescence labeling experiment revealed that <italic>hk-B.f</italic> transiently stayed in gastrointestinal tract (mainly in the upper digestive tract) and did not colonize extra-gastrointestinal organs. Thus, <italic>hk-B.&#x000a0;f</italic> supplementation may be a safe and effective strategy for CID warranting further clinical trials, particularly as the heat-killed formulation mitigates the potential risk of living bacteria in immunocompromised chemotherapy patients [<xref ref-type="bibr" rid="CR2">2</xref>].</p><p id="Par71">We present further evidence that <italic>hk-B.&#x000a0;f</italic> improves CID by reducing 5-FU-induced activation of the mitochondrial apoptosis pathway in ileal epithelial cells. Apoptosis is a tightly controlled process that involves three major signaling pathways [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]: mitochondrial, endoplasmic reticulum, and death receptor. The intrinsic mitochondrial pathway is regulated primarily by BCL2 proteins, which bind and inactivate proapoptotic pore-forming BAX proteins [<xref ref-type="bibr" rid="CR38">38</xref>&#x02013;<xref ref-type="bibr" rid="CR40">40</xref>]. Activation of BAX at the mitochondrial surface leads to mitochondrial outer membrane permeabilization (MOMP) [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref>], ensuring the release of apoptogenic proteins from the intermembrane space, and activation of the caspases, a family of cysteine proteases [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR43">43</xref>&#x02013;<xref ref-type="bibr" rid="CR45">45</xref>]. Caspases are classified into two groups [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]: initiator caspases such as caspase-9 and effector caspases such as caspase-3. Our TEM study of ileal tissue revealed that 5-FU damaged intestinal mitochondria and resulted in a relatively higher level of TUNEL-positive (apoptotic) cells, especially in the ileal crypt containing highly proliferative stem cells. This finding is consistent with a previous study showing that oxaliplatin-based chemotherapy-induced apoptosis mainly located at the crypts of human ilea [<xref ref-type="bibr" rid="CR46">46</xref>]. We further demonstrated that <italic>hk-B.&#x000a0;f</italic> could alleviate mitochondrial apoptosis by reversing the 5-FU-induced reduction in BCL2 expression and suppressing the 5-FU-induced upregulation of BAX expression. These results were further supported by in vitro experiments using the IEC-6 cell line and small intestinal organoids.</p><p id="Par72">Many studies, including our previous work, have revealed that the living state of probiotics is essential for its beneficial effects, indicating that the secreted bioactive products play a key role in maintaining host homoeostasis [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR47">47</xref>&#x02013;<xref ref-type="bibr" rid="CR52">52</xref>]. Heat-inactivation partly preserves cellular components and denatures metabolites [<xref ref-type="bibr" rid="CR53">53</xref>]. Thus, it is an interesting finding that <italic>hk-B.&#x000a0;f</italic> has better therapeutic effects than live <italic>B.&#x000a0;f</italic> on CID model. It is worth mentioning that several inactivated probiotics, including <italic>Akkermansia muciniphila</italic> and <italic>Bifidobacterium bifidum</italic>, had better efficacy on diseases [<xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR55">55</xref>]. How inactivation enhances the effects of live bacteria remains to be elucidated.</p><p id="Par73">The underlying mechanism is complex and may involve several potential possibilities. One possibility is that a certain component in live <italic>B.&#x000a0;f</italic>-derived metabolites is detrimental to CID, thus weakening the probiotic effect of bacterial structure. Therefore, we detected the main metabolite composition in live <italic>B.&#x000a0;f</italic> culture supernatant. The content of SA and PA markedly changed. SA, one kind of organic acid secreted from live <italic>B.f</italic> has been detected to act as a danger factor driving the progression of CID. Previous studies also illustrated that succinate derived from mitochondrial metabolism is known to initiate and propagate danger signals from tissue injury [<xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR57">57</xref>]. Unexpectedly, PA, one of the short-chain fatty acids (SCFAs), had no significant effect on 5-FU induced diarrhea despite it serves as a potent immunomodulator supplement in many other disease models [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR58">58</xref>&#x02013;<xref ref-type="bibr" rid="CR60">60</xref>]. Further, we isolated and purified capsular PS from <italic>B.&#x000a0;f</italic> strain ZY-312. <italic>B.&#x000a0;f</italic> standard strain and its immunomodulatory capsular PSA have been extensively studied and shown to be equally effective in preventing colitis and experimental allergic encephalomyelitis in murine models [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR61">61</xref>]. The immunomodulatory activities of PSA induce regulatory T cells secreting IL-10, a potent anti-inflammatory cytokine that restrains pathogenic inflammation in the gut [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR62">62</xref>]. In this research, <italic>B.&#x000a0;f</italic> strain ZY-312-derived capsular PSA, TP2, effectively maintain mice body weight, alleviate diarrhea, decrease fecal water content, and protect intestinal leakage. Collectively, these findings indicated that <italic>B.f</italic>-secreted succinic acid weakened the probiotic effect of capsule polysaccharides TP2 on CID which may explain the discrepant therapeutic effect between <italic>hk-B.&#x000a0;f</italic> and live <italic>B.&#x000a0;f</italic>.</p><p id="Par74">This study has several limitations. First, while our metagenomic sequencing provides insights into taxonomic and functional shifts, we acknowledge that metagenomic binning was not performed. Second, animal experiments were conducted exclusively on male mice, so the relevance of these findings in female group requires future studies. Moreover, the mechanism by which <italic>hk-B.&#x000a0;f</italic>/TP2 is recognized by immune cells and subsequently affects the mitochondrial apoptosis pathway in intestinal epithelial cells were not been carefully studied and elucidated. Future research is needed to address this issue.</p></sec><sec id="Sec25"><title>Conclusions</title><p id="Par75">Finally, our study demonstrates that the pathological process of CID can be at least partially explained by compositional alterations in gut microbiota, especially <italic>B.&#x000a0;f</italic>. A hurdle to the use of live <italic>B.&#x000a0;f</italic> is its high sensitivity to oxygen. Here, we show that non-replicative, <italic>hk-B.&#x000a0;f</italic> had the satisfying effect on ameliorating diarrhea and intestinal apoptosis via BCL2-mediated mitochondrial-apoptotic pathway in preclinical CID models. These results pave the way for future human studies investigating <italic>hk-B.&#x000a0;f</italic> as a therapeutic tool in the management of intolerable side effects from anti-tumor therapy.</p></sec><sec id="Sec118" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12916_2025_4233_MOESM1_ESM.docx"><caption><p>Additional file 1: Supplementary Methods.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="12916_2025_4233_MOESM2_ESM.docx"><caption><p>Additional file 2: Fig. S1-S10. Fig. S1- Fecal microbial differential and functional analysis. Fig. S2&#x02014;Bacterial diversity of different doses of <italic>hk-B.f</italic> administrated to 5-FU-induced CID mice. Fig. S3&#x02014;Rescue experiments in IEC-6 cell line in vitro. Fig. S4&#x02014;The effect of probiotics on CPT-11 induced CID model in mice. Fig. S5&#x02014;The effect of different doses of <italic>hk-B.f</italic> on CPT-11 stimulated CID model in mice. Fig. S6&#x02014;In vivo optical imaging of <italic>hk-B.f</italic> via metabolic labeling. Fig. S7&#x02014;Imaging of mice&#x02019;s stomach using confocal microscopy. Fig. S8&#x02014;Imaging of mice&#x02019;s ileum using confocal microscopy. Fig. S9&#x02014;Imaging of mice&#x02019;s colon using confocal microscopy. Fig. S10&#x02014;Graphic abstract.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="12916_2025_4233_MOESM3_ESM.docx"><caption><p>Additional file 3: Full length uncropped original western blots.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM4"><media xlink:href="12916_2025_4233_MOESM4_ESM.pdf"><caption><p>Additional file 4: ARRIVE checklist.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM5"><media xlink:href="12916_2025_4233_MOESM5_ESM.doc"><caption><p>Additional file 5: STROBE checklist.</p></caption></media></supplementary-material></p></sec></body><back><glossary id="AGS1"><title>Abbreviations</title><def-list><def-item><term>5-FU</term><def><p id="Par11">5-Fluorouracil</p></def></def-item><def-item><term><italic>B. f</italic></term><def><p id="Par12">
<italic>Bacteroides</italic>
<italic> fragilis</italic>
</p></def></def-item><def-item><term>CID</term><def><p id="Par13">Chemotherapy-induced diarrhea</p></def></def-item><def-item><term>CPT-11</term><def><p id="Par14">Irinotecan</p></def></def-item><def-item><term>FITC-Dextran</term><def><p id="Par15">Fluorescein isothiocyanate</p></def></def-item><def-item><term><italic>hk-B.&#x000a0;f</italic></term><def><p id="Par16">Heat-killed<italic> Bacteroides fragilis</italic></p></def></def-item><def-item><term><italic>hk-B.&#x000a0;f</italic>(H)</term><def><p id="Par17">High-dose of <italic>hk-B.&#x000a0;f</italic></p></def></def-item><def-item><term><italic>hk-B.&#x000a0;f</italic>(L)</term><def><p id="Par18">Low-dose of <italic>hk-B.&#x000a0;f</italic></p></def></def-item><def-item><term><italic>hk-B.&#x000a0;f</italic>(M)</term><def><p id="Par19">Medium-dose of <italic>hk-B.&#x000a0;f</italic></p></def></def-item><def-item><term>KEGG</term><def><p id="Par20">Kyoto Encyclopedia of Genes and Genomes</p></def></def-item><def-item><term>LPM</term><def><p id="Par21">Loperamide</p></def></def-item><def-item><term>MOMP</term><def><p id="Par22">Mitochondrial outer membrane permeabilization</p></def></def-item><def-item><term>PA</term><def><p id="Par23">Propionic acid</p></def></def-item><def-item><term>PB3</term><def><p id="Par24">Triple probiotics combination of living <italic>Bifidobacterium longum</italic>, <italic>Lactobacillus acidophilus</italic> and <italic>Streptococcus faecalis</italic></p></def></def-item><def-item><term>Post</term><def><p id="Par25">Post-chemotherapy group</p></def></def-item><def-item><term>Pre</term><def><p id="Par26">Pre-chemotherapy group</p></def></def-item><def-item><term>SA</term><def><p id="Par27">Succinic acid</p></def></def-item><def-item><term>SCFAs</term><def><p id="Par28">Short-chain fatty acids</p></def></def-item><def-item><term>SEM</term><def><p id="Par29">Scanning electron microscopy</p></def></def-item><def-item><term>TEER</term><def><p id="Par30">Trans-epithelial elective resistance</p></def></def-item><def-item><term>TEM</term><def><p id="Par31">Transmission electron microscopy</p></def></def-item><def-item><term>TP2</term><def><p id="Par32">Capsular polysaccharides isolated and purified from <italic>Bacteroides fragilis</italic> strain ZY-312</p></def></def-item><def-item><term>Z</term><def><p id="Par33">Z-VAD-FMK</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Xinwen Yan and Xinlong Lin contributed equally to this works.</p></fn></fn-group><ack><title>Acknowledgements
</title><p>The authors would like to thank all the study participants and medical professionals at the Nanfang hospital of Southern medical university for their time and participation. We thank XYH for artwork painting.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions
</title><p>XWY, WJL and FCZ conceptualized of the project. XWY, JHW and WJL managed the resources of clinical specimens. FW, YYL, PL and FCZ acquired research funding to the study. XWY and LJZ performed and analyzed the experiments.XWY and XLL wrote the manuscript with the input of co-authors. YL, YSL, CYH, BHS, HBL, RH, FYH, QZ, MYS, KL, FQZ, SL, YQL and WW provided the technical support. All authors read and approved the final manuscript. FCZ is the guarantor of this study.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by Study on the Mechanism of FUT7 regulating CD15s&#x02009;+&#x02009;eTreg cells in the Pathogenesis of Ulcerative Colitis (Y20190159), Innovation Leading Team Project in Guangzhou (NO. 201809010014) and Key Technology Project in Guangzhou (NO.2024B03J1282).</p></notes><notes notes-type="data-availability"><title>Data availability
</title><p>Metagenomic and RNA-Seq raw sequence data have been deposited in Sequence Read Archive with primary accession code PRJNA1010108. Non-targeted metabolomics raw sequence data have been deposited in MetaboLights with primary accession code MTBLS12404. 16S RNA raw sequence data have been deposited in Sequence Read Archive with primary accession code PRJNA1258387. These data are publicly available as of the date of publication. All data reported in this paper will be shared by the lead contact upon request.</p></notes><notes><title>Declarations</title><notes id="FPar2"><title>Ethics approval and consent to participate</title><p id="Par76">All procedures involving pathological sample collection and usage were according to the guideline of the Ethics Committee of Nanfang Hospital of Southern Medical University (NFEC-2020&#x02013;269). All participants gave their informed consent. All animal study protocols were approved by Institutional Animal Care and Use Committee at Southern Medical University (K2021035).</p></notes><notes id="FPar3"><title>Consent for publication</title><p id="Par77">Not applicable.</p></notes><notes id="FPar4" notes-type="COI-statement"><title>Competing interests
</title><p id="Par78">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Andreyev</surname><given-names>J</given-names></name><name><surname>Ross</surname><given-names>P</given-names></name><name><surname>Donnellan</surname><given-names>C</given-names></name><name><surname>Lennan</surname><given-names>E</given-names></name><name><surname>Leonard</surname><given-names>P</given-names></name><name><surname>Waters</surname><given-names>C</given-names></name><etal/></person-group><article-title>Guidance on the management of diarrhoea during cancer chemotherapy</article-title><source>Lancet Oncol</source><year>2014</year><volume>15</volume><issue>10</issue><fpage>e447</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(14)70006-3</pub-id><?supplied-pmid 25186048?><pub-id pub-id-type="pmid">25186048</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Andreyev J, Ross P, Donnellan C, Lennan E, Leonard P, Waters C, et al. Guidance on the management of diarrhoea during cancer chemotherapy. Lancet Oncol. 2014;15(10):e447-460.<pub-id pub-id-type="pmid">25186048</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Bossi</surname><given-names>P</given-names></name><name><surname>Antonuzzo</surname><given-names>A</given-names></name><name><surname>Cherny</surname><given-names>NI</given-names></name><name><surname>Rosengarten</surname><given-names>O</given-names></name><name><surname>Pernot</surname><given-names>S</given-names></name><name><surname>Trippa</surname><given-names>F</given-names></name><etal/></person-group><article-title>Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines</article-title><source>Ann Oncol</source><year>2018</year><volume>29</volume><issue>4</issue><fpage>iv126</fpage><lpage>iv142</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdy145</pub-id><?supplied-pmid 29931177?><pub-id pub-id-type="pmid">29931177</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Bossi P, Antonuzzo A, Cherny NI, Rosengarten O, Pernot S, Trippa F, et al. Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2018;29(4):iv126&#x02013;42.<pub-id pub-id-type="pmid">29931177</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Wadler</surname><given-names>S</given-names></name><name><surname>Benson</surname><given-names>AB</given-names><suffix>3rd</suffix></name><name><surname>Engelking</surname><given-names>C</given-names></name><name><surname>Catalano</surname><given-names>R</given-names></name><name><surname>Field</surname><given-names>M</given-names></name><etal/></person-group><article-title>Recommended guidelines for the treatment of chemotherapy-induced diarrhea</article-title><source>J Clin Oncol</source><year>1998</year><volume>16</volume><issue>9</issue><fpage>3169</fpage><lpage>3178</lpage><pub-id pub-id-type="doi">10.1200/JCO.1998.16.9.3169</pub-id><?supplied-pmid 9738589?><pub-id pub-id-type="pmid">9738589</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Wadler S, Benson AB 3rd, Engelking C, Catalano R, Field M, et al. Recommended guidelines for the treatment of chemotherapy-induced diarrhea. J Clin Oncol. 1998;16(9):3169&#x02013;78.<pub-id pub-id-type="pmid">9738589</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Akbarali</surname><given-names>HI</given-names></name><name><surname>Muchhala</surname><given-names>KH</given-names></name><name><surname>Jessup</surname><given-names>DK</given-names></name><name><surname>Cheatham</surname><given-names>S</given-names></name></person-group><article-title>Chemotherapy induced gastrointestinal toxicities</article-title><source>Adv Cancer Res</source><year>2022</year><volume>155</volume><fpage>131</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1016/bs.acr.2022.02.007</pub-id><?supplied-pmid 35779873?><pub-id pub-id-type="pmid">35779873</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Akbarali HI, Muchhala KH, Jessup DK, Cheatham S. Chemotherapy induced gastrointestinal toxicities. Adv Cancer Res. 2022;155:131&#x02013;66.<pub-id pub-id-type="pmid">35779873</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Coakley</surname><given-names>G</given-names></name><name><surname>Harris</surname><given-names>NL</given-names></name></person-group><article-title>The Intestinal Epithelium at the Forefront of Host-Helminth Interactions</article-title><source>Trends Parasitol</source><year>2020</year><volume>36</volume><issue>9</issue><fpage>761</fpage><lpage>772</lpage><pub-id pub-id-type="doi">10.1016/j.pt.2020.07.002</pub-id><?supplied-pmid 32713764?><pub-id pub-id-type="pmid">32713764</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Coakley G, Harris NL. The Intestinal Epithelium at the Forefront of Host-Helminth Interactions. Trends Parasitol. 2020;36(9):761&#x02013;72.<pub-id pub-id-type="pmid">32713764</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Allaire</surname><given-names>JM</given-names></name><name><surname>Crowley</surname><given-names>SM</given-names></name><name><surname>Law</surname><given-names>HT</given-names></name><name><surname>Chang</surname><given-names>SY</given-names></name><name><surname>Ko</surname><given-names>HJ</given-names></name><name><surname>Vallance</surname><given-names>BA</given-names></name></person-group><article-title>The Intestinal Epithelium: Central Coordinator of Mucosal Immunity</article-title><source>Trends Immunol</source><year>2018</year><volume>39</volume><issue>9</issue><fpage>677</fpage><lpage>696</lpage><pub-id pub-id-type="doi">10.1016/j.it.2018.04.002</pub-id><?supplied-pmid 29716793?><pub-id pub-id-type="pmid">29716793</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Allaire JM, Crowley SM, Law HT, Chang SY, Ko HJ, Vallance BA. The Intestinal Epithelium: Central Coordinator of Mucosal Immunity. Trends Immunol. 2018;39(9):677&#x02013;96.<pub-id pub-id-type="pmid">29716793</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Chrysostomou</surname><given-names>D</given-names></name><name><surname>Roberts</surname><given-names>LA</given-names></name><name><surname>Marchesi</surname><given-names>JR</given-names></name><name><surname>Kinross</surname><given-names>JM</given-names></name></person-group><article-title>Gut Microbiota Modulation of Efficacy and Toxicity of Cancer Chemotherapy and Immunotherapy</article-title><source>Gastroenterology</source><year>2023</year><volume>164</volume><issue>2</issue><fpage>198</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2022.10.018</pub-id><?supplied-pmid 36309208?><pub-id pub-id-type="pmid">36309208</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Chrysostomou D, Roberts LA, Marchesi JR, Kinross JM. Gut Microbiota Modulation of Efficacy and Toxicity of Cancer Chemotherapy and Immunotherapy. Gastroenterology. 2023;164(2):198&#x02013;213.<pub-id pub-id-type="pmid">36309208</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Stringer</surname><given-names>AM</given-names></name><name><surname>Al-Dasooqi</surname><given-names>N</given-names></name><name><surname>Bowen</surname><given-names>JM</given-names></name><name><surname>Tan</surname><given-names>TH</given-names></name><name><surname>Radzuan</surname><given-names>M</given-names></name><name><surname>Logan</surname><given-names>RM</given-names></name><etal/></person-group><article-title>Biomarkers of chemotherapy-induced diarrhoea: a clinical study of intestinal microbiome alterations, inflammation and circulating matrix metalloproteinases</article-title><source>Support Care Cancer</source><year>2013</year><volume>21</volume><issue>7</issue><fpage>1843</fpage><lpage>1852</lpage><pub-id pub-id-type="doi">10.1007/s00520-013-1741-7</pub-id><?supplied-pmid 23397098?><pub-id pub-id-type="pmid">23397098</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Stringer AM, Al-Dasooqi N, Bowen JM, Tan TH, Radzuan M, Logan RM, et al. Biomarkers of chemotherapy-induced diarrhoea: a clinical study of intestinal microbiome alterations, inflammation and circulating matrix metalloproteinases. Support Care Cancer. 2013;21(7):1843&#x02013;52.<pub-id pub-id-type="pmid">23397098</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Stringer</surname><given-names>AM</given-names></name></person-group><article-title>Interaction between host cells and microbes in chemotherapy-induced mucositis</article-title><source>Nutrients</source><year>2013</year><volume>5</volume><issue>5</issue><fpage>1488</fpage><lpage>1499</lpage><pub-id pub-id-type="doi">10.3390/nu5051488</pub-id><?supplied-pmid 23628721?><pub-id pub-id-type="pmid">23628721</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Stringer AM. Interaction between host cells and microbes in chemotherapy-induced mucositis. Nutrients. 2013;5(5):1488&#x02013;99.<pub-id pub-id-type="pmid">23628721</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="other">Sahi N, Nguyen R, Patel P, Santos C. Loperamide. In: StatPearls [internet]. Treasure Island (FL): StatPearls Publishing; 2025.</mixed-citation></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>PE</given-names></name><name><surname>Juurlink</surname><given-names>DN</given-names></name></person-group><article-title>Clinical Review: Loperamide Toxicity</article-title><source>Ann Emerg Med</source><year>2017</year><volume>70</volume><issue>2</issue><fpage>245</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1016/j.annemergmed.2017.04.008</pub-id><?supplied-pmid 28506439?><pub-id pub-id-type="pmid">28506439</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Wu PE, Juurlink DN. Clinical Review: Loperamide Toxicity. Ann Emerg Med. 2017;70(2):245&#x02013;52.<pub-id pub-id-type="pmid">28506439</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Cascinu</surname><given-names>S</given-names></name><name><surname>Fedeli</surname><given-names>A</given-names></name><name><surname>Fedeli</surname><given-names>SL</given-names></name><name><surname>Catalano</surname><given-names>G</given-names></name></person-group><article-title>Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial</article-title><source>J Clin Oncol</source><year>1993</year><volume>11</volume><issue>1</issue><fpage>148</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1200/JCO.1993.11.1.148</pub-id><?supplied-pmid 8418225?><pub-id pub-id-type="pmid">8418225</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Cascinu S, Fedeli A, Fedeli SL, Catalano G. Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial. J Clin Oncol. 1993;11(1):148&#x02013;51.<pub-id pub-id-type="pmid">8418225</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>T</given-names></name><name><surname>Uhder</surname><given-names>K</given-names></name><name><surname>Kurek</surname><given-names>R</given-names></name><name><surname>Roeddiger</surname><given-names>S</given-names></name><name><surname>Schneider</surname><given-names>L</given-names></name><name><surname>Vogt</surname><given-names>HG</given-names></name><etal/></person-group><article-title>Does prophylactic treatment with proteolytic enzymes reduce acute toxicity of adjuvant pelvic irradiation? Results of a double-blind randomized trial</article-title><source>Radiother Oncol</source><year>2002</year><volume>65</volume><issue>1</issue><fpage>17</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/S0167-8140(02)00192-5</pub-id><?supplied-pmid 12413670?><pub-id pub-id-type="pmid">12413670</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Martin T, Uhder K, Kurek R, Roeddiger S, Schneider L, Vogt HG, et al. Does prophylactic treatment with proteolytic enzymes reduce acute toxicity of adjuvant pelvic irradiation? Results of a double-blind randomized trial. Radiother Oncol. 2002;65(1):17&#x02013;22.<pub-id pub-id-type="pmid">12413670</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Qian</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Bacteroides fragilis Prevents Clostridium difficile Infection in a Mouse Model by Restoring Gut Barrier and Microbiome Regulation</article-title><source>Front Microbiol</source><year>2018</year><volume>9</volume><fpage>2976</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2018.02976</pub-id><?supplied-pmid 30619112?><pub-id pub-id-type="pmid">30619112</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Deng H, Yang S, Zhang Y, Qian K, Zhang Z, Liu Y, et al. Bacteroides fragilis Prevents Clostridium difficile Infection in a Mouse Model by Restoring Gut Barrier and Microbiome Regulation. Front Microbiol. 2018;9:2976.<pub-id pub-id-type="pmid">30619112</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Zhu</surname><given-names>B</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Qiu</surname><given-names>E</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Bacteroides fragilis Protects Against Antibiotic-Associated Diarrhea in Rats by Modulating Intestinal Defenses</article-title><source>Front Immunol</source><year>2018</year><volume>9</volume><fpage>1040</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.01040</pub-id><?supplied-pmid 29868005?><pub-id pub-id-type="pmid">29868005</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Zhang W, Zhu B, Xu J, Liu Y, Qiu E, Li Z, et al. Bacteroides fragilis Protects Against Antibiotic-Associated Diarrhea in Rats by Modulating Intestinal Defenses. Front Immunol. 2018;9:1040.<pub-id pub-id-type="pmid">29868005</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Delia</surname><given-names>P</given-names></name><name><surname>Sansotta</surname><given-names>G</given-names></name><name><surname>Donato</surname><given-names>V</given-names></name><name><surname>Frosina</surname><given-names>P</given-names></name><name><surname>Messina</surname><given-names>G</given-names></name><name><surname>De Renzis</surname><given-names>C</given-names></name><etal/></person-group><article-title>Use of probiotics for prevention of radiation-induced diarrhea</article-title><source>World J Gastroenterol</source><year>2007</year><volume>13</volume><issue>6</issue><fpage>912</fpage><lpage>915</lpage><pub-id pub-id-type="doi">10.3748/wjg.v13.i6.912</pub-id><?supplied-pmid 17352022?><pub-id pub-id-type="pmid">17352022</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Delia P, Sansotta G, Donato V, Frosina P, Messina G, De Renzis C, et al. Use of probiotics for prevention of radiation-induced diarrhea. World J Gastroenterol. 2007;13(6):912&#x02013;5.<pub-id pub-id-type="pmid">17352022</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Osterlund</surname><given-names>P</given-names></name><name><surname>Ruotsalainen</surname><given-names>T</given-names></name><name><surname>Korpela</surname><given-names>R</given-names></name><name><surname>Saxelin</surname><given-names>M</given-names></name><name><surname>Ollus</surname><given-names>A</given-names></name><name><surname>Valta</surname><given-names>P</given-names></name><etal/></person-group><article-title>Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study</article-title><source>Br J Cancer</source><year>2007</year><volume>97</volume><issue>8</issue><fpage>1028</fpage><lpage>1034</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6603990</pub-id><?supplied-pmid 17895895?><pub-id pub-id-type="pmid">17895895</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Osterlund P, Ruotsalainen T, Korpela R, Saxelin M, Ollus A, Valta P, et al. Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. Br J Cancer. 2007;97(8):1028&#x02013;34.<pub-id pub-id-type="pmid">17895895</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>B</given-names></name><name><surname>Pan</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Ye</surname><given-names>Z</given-names></name><name><surname>Yuan</surname><given-names>H</given-names></name><etal/></person-group><article-title>Oyster polysaccharides ameliorate intestinal mucositis and improve metabolism in 5-fluorouracil-treated S180 tumour-bearing mice</article-title><source>Carbohydr Polym</source><year>2021</year><volume>256</volume><fpage>117545</fpage><pub-id pub-id-type="doi">10.1016/j.carbpol.2020.117545</pub-id><?supplied-pmid 33483054?><pub-id pub-id-type="pmid">33483054</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Cai B, Pan J, Chen H, Chen X, Ye Z, Yuan H, et al. Oyster polysaccharides ameliorate intestinal mucositis and improve metabolism in 5-fluorouracil-treated S180 tumour-bearing mice. Carbohydr Polym. 2021;256: 117545.<pub-id pub-id-type="pmid">33483054</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wei</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Zhong</surname><given-names>H</given-names></name><etal/></person-group><article-title>DNA damage repair promotion in colonic epithelial cells by andrographolide downregulated cGAS-STING pathway activation and contributed to the relief of CPT-11-induced intestinal mucositis</article-title><source>Acta Pharm Sin B</source><year>2022</year><volume>12</volume><issue>1</issue><fpage>262</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1016/j.apsb.2021.03.043</pub-id><?supplied-pmid 35127384?><pub-id pub-id-type="pmid">35127384</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Wang Y, Wei B, Wang D, Wu J, Gao J, Zhong H, et al. DNA damage repair promotion in colonic epithelial cells by andrographolide downregulated cGAS-STING pathway activation and contributed to the relief of CPT-11-induced intestinal mucositis. Acta Pharm Sin B. 2022;12(1):262&#x02013;73.<pub-id pub-id-type="pmid">35127384</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>C</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><etal/></person-group><article-title>a MapReduce acceleration-supported software for integrated quality control and preprocessing of high-throughput sequencing data</article-title><source>Gigascience</source><year>2018</year><volume>7</volume><issue>1</issue><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1093/gigascience/gix120</pub-id><?supplied-pmid 29659813?><pub-id pub-id-type="pmid">29659813</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Chen Y, Chen Y, Shi C, Huang Z, Zhang Y, Li S, et al. a MapReduce acceleration-supported software for integrated quality control and preprocessing of high-throughput sequencing data. Gigascience. 2018;7(1):1&#x02013;6.<pub-id pub-id-type="pmid">29659813</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Yu</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Lam</surname><given-names>TW</given-names></name><name><surname>Yiu</surname><given-names>SM</given-names></name><name><surname>Kristiansen</surname><given-names>K</given-names></name><etal/></person-group><article-title>SOAP2: an improved ultrafast tool for short read alignment</article-title><source>Bioinformatics</source><year>2009</year><volume>25</volume><issue>15</issue><fpage>1966</fpage><lpage>1967</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp336</pub-id><?supplied-pmid 19497933?><pub-id pub-id-type="pmid">19497933</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Li R, Yu C, Li Y, Lam TW, Yiu SM, Kristiansen K, et al. SOAP2: an improved ultrafast tool for short read alignment. Bioinformatics. 2009;25(15):1966&#x02013;7.<pub-id pub-id-type="pmid">19497933</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>CM</given-names></name><name><surname>Luo</surname><given-names>R</given-names></name><name><surname>Sadakane</surname><given-names>K</given-names></name><name><surname>Lam</surname><given-names>TW</given-names></name></person-group><article-title>MEGAHIT: an ultra-fast single-node solution for large and complex metagenomics assembly via succinct de Bruijn graph</article-title><source>Bioinformatics</source><year>2015</year><volume>31</volume><issue>10</issue><fpage>1674</fpage><lpage>1676</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btv033</pub-id><?supplied-pmid 25609793?><pub-id pub-id-type="pmid">25609793</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Li D, Liu CM, Luo R, Sadakane K, Lam TW. MEGAHIT: an ultra-fast single-node solution for large and complex metagenomics assembly via succinct de Bruijn graph. Bioinformatics. 2015;31(10):1674&#x02013;6.<pub-id pub-id-type="pmid">25609793</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>W</given-names></name><name><surname>Lomsadze</surname><given-names>A</given-names></name><name><surname>Borodovsky</surname><given-names>M</given-names></name></person-group><article-title>Ab initio gene identification in metagenomic sequences</article-title><source>Nucleic Acids Res</source><year>2010</year><volume>38</volume><issue>12</issue><fpage>e132</fpage><pub-id pub-id-type="doi">10.1093/nar/gkq275</pub-id><?supplied-pmid 20403810?><pub-id pub-id-type="pmid">20403810</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Zhu W, Lomsadze A, Borodovsky M. Ab initio gene identification in metagenomic sequences. Nucleic Acids Res. 2010;38(12): e132.<pub-id pub-id-type="pmid">20403810</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>L</given-names></name><name><surname>Niu</surname><given-names>B</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>W</given-names></name></person-group><article-title>CD-HIT: accelerated for clustering the next-generation sequencing data</article-title><source>Bioinformatics</source><year>2012</year><volume>28</volume><issue>23</issue><fpage>3150</fpage><lpage>3152</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts565</pub-id><?supplied-pmid 23060610?><pub-id pub-id-type="pmid">23060610</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Fu L, Niu B, Zhu Z, Wu S, Li W. CD-HIT: accelerated for clustering the next-generation sequencing data. Bioinformatics. 2012;28(23):3150&#x02013;2.<pub-id pub-id-type="pmid">23060610</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Wood</surname><given-names>DE</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Langmead</surname><given-names>B</given-names></name></person-group><article-title>Improved metagenomic analysis with Kraken 2</article-title><source>Genome Biol</source><year>2019</year><volume>20</volume><issue>1</issue><fpage>257</fpage><pub-id pub-id-type="doi">10.1186/s13059-019-1891-0</pub-id><?supplied-pmid 31779668?><pub-id pub-id-type="pmid">31779668</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Wood DE, Lu J, Langmead B. Improved metagenomic analysis with Kraken 2. Genome Biol. 2019;20(1):257.<pub-id pub-id-type="pmid">31779668</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>He</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Tang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Protein C receptor maintains cancer stem cell properties via activating lipid synthesis in nasopharyngeal carcinoma</article-title><source>Signal Transduct Target Ther</source><year>2022</year><volume>7</volume><issue>1</issue><fpage>46</fpage><pub-id pub-id-type="doi">10.1038/s41392-021-00866-z</pub-id><?supplied-pmid 35169126?><pub-id pub-id-type="pmid">35169126</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Zhang P, He Q, Wang Y, Zhou G, Chen Y, Tang L, et al. Protein C receptor maintains cancer stem cell properties via activating lipid synthesis in nasopharyngeal carcinoma. Signal Transduct Target Ther. 2022;7(1):46.<pub-id pub-id-type="pmid">35169126</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Katchar</surname><given-names>K</given-names></name><name><surname>Goldsmith</surname><given-names>JD</given-names></name><name><surname>Nanthakumar</surname><given-names>N</given-names></name><name><surname>Cheknis</surname><given-names>A</given-names></name><name><surname>Gerding</surname><given-names>DN</given-names></name><etal/></person-group><article-title>A mouse model of Clostridium difficile-associated disease</article-title><source>Gastroenterology</source><year>2008</year><volume>135</volume><issue>6</issue><fpage>1984</fpage><lpage>1992</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2008.09.002</pub-id><?supplied-pmid 18848941?><pub-id pub-id-type="pmid">18848941</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Chen X, Katchar K, Goldsmith JD, Nanthakumar N, Cheknis A, Gerding DN, et al. A mouse model of Clostridium difficile-associated disease. Gastroenterology. 2008;135(6):1984&#x02013;92.<pub-id pub-id-type="pmid">18848941</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Wenzl</surname><given-names>HH</given-names></name><name><surname>Fine</surname><given-names>KD</given-names></name><name><surname>Schiller</surname><given-names>LR</given-names></name><name><surname>Fordtran</surname><given-names>JS</given-names></name></person-group><article-title>Determinants of decreased fecal consistency in patients with diarrhea</article-title><source>Gastroenterology</source><year>1995</year><volume>108</volume><issue>6</issue><fpage>1729</fpage><lpage>1738</lpage><pub-id pub-id-type="doi">10.1016/0016-5085(95)90134-5</pub-id><?supplied-pmid 7768377?><pub-id pub-id-type="pmid">7768377</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Wenzl HH, Fine KD, Schiller LR, Fordtran JS. Determinants of decreased fecal consistency in patients with diarrhea. Gastroenterology. 1995;108(6):1729&#x02013;38.<pub-id pub-id-type="pmid">7768377</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="other">Li BR, Wu J, Li HS, Jiang ZH, Zhou XM, Xu CH, et al. In vitro and in vivo approaches to determine intestinal epithelial cell permeability. J Vis Exp 2018;140:57032.</mixed-citation></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>L</given-names></name><name><surname>Luo</surname><given-names>M</given-names></name><name><surname>Kuang</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Liang</surname><given-names>D</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Capsular Polysaccharide From Bacteroides fragilis Protects Against Ulcerative Colitis in an Undegraded Form</article-title><source>Front Pharmacol</source><year>2020</year><volume>11</volume><fpage>570476</fpage><pub-id pub-id-type="doi">10.3389/fphar.2020.570476</pub-id><?supplied-pmid 33364945?><pub-id pub-id-type="pmid">33364945</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Zheng L, Luo M, Kuang G, Liu Y, Liang D, Huang H, et al. Capsular Polysaccharide From Bacteroides fragilis Protects Against Ulcerative Colitis in an Undegraded Form. Front Pharmacol. 2020;11: 570476.<pub-id pub-id-type="pmid">33364945</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>XH</given-names></name></person-group><article-title>Effect of caseinate glycation with oligochitosan and transglutaminase on the intestinal barrier function of the tryptic caseinate digest in IEC-6 cells</article-title><source>Food Funct</source><year>2019</year><volume>10</volume><issue>2</issue><fpage>652</fpage><lpage>664</lpage><pub-id pub-id-type="doi">10.1039/C8FO01785A</pub-id><?supplied-pmid 30652176?><pub-id pub-id-type="pmid">30652176</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Shi J, Zhao XH. Effect of caseinate glycation with oligochitosan and transglutaminase on the intestinal barrier function of the tryptic caseinate digest in IEC-6 cells. Food Funct. 2019;10(2):652&#x02013;64.<pub-id pub-id-type="pmid">30652176</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Mollica</surname><given-names>MP</given-names></name><name><surname>Mattace Raso</surname><given-names>G</given-names></name><name><surname>Cavaliere</surname><given-names>G</given-names></name><name><surname>Trinchese</surname><given-names>G</given-names></name><name><surname>De Filippo</surname><given-names>C</given-names></name><name><surname>Aceto</surname><given-names>S</given-names></name><etal/></person-group><article-title>Butyrate Regulates Liver Mitochondrial Function, Efficiency, and Dynamics in Insulin-Resistant Obese Mice</article-title><source>Diabetes</source><year>2017</year><volume>66</volume><issue>5</issue><fpage>1405</fpage><lpage>1418</lpage><pub-id pub-id-type="doi">10.2337/db16-0924</pub-id><?supplied-pmid 28223285?><pub-id pub-id-type="pmid">28223285</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Mollica MP, Mattace Raso G, Cavaliere G, Trinchese G, De Filippo C, Aceto S, et al. Butyrate Regulates Liver Mitochondrial Function, Efficiency, and Dynamics in Insulin-Resistant Obese Mice. Diabetes. 2017;66(5):1405&#x02013;18.<pub-id pub-id-type="pmid">28223285</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>Z</given-names></name><name><surname>Guo</surname><given-names>S</given-names></name><name><surname>Copps</surname><given-names>K</given-names></name><name><surname>Dong</surname><given-names>X</given-names></name><name><surname>Kollipara</surname><given-names>R</given-names></name><name><surname>Rodgers</surname><given-names>JT</given-names></name><etal/></person-group><article-title>Foxo1 integrates insulin signaling with mitochondrial function in the liver</article-title><source>Nat Med</source><year>2009</year><volume>15</volume><issue>11</issue><fpage>1307</fpage><lpage>1311</lpage><pub-id pub-id-type="doi">10.1038/nm.2049</pub-id><?supplied-pmid 19838201?><pub-id pub-id-type="pmid">19838201</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Cheng Z, Guo S, Copps K, Dong X, Kollipara R, Rodgers JT, et al. Foxo1 integrates insulin signaling with mitochondrial function in the liver. Nat Med. 2009;15(11):1307&#x02013;11.<pub-id pub-id-type="pmid">19838201</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Mazmanian</surname><given-names>SK</given-names></name><name><surname>Round</surname><given-names>JL</given-names></name><name><surname>Kasper</surname><given-names>DL</given-names></name></person-group><article-title>A microbial symbiosis factor prevents intestinal inflammatory disease</article-title><source>Nature</source><year>2008</year><volume>453</volume><issue>7195</issue><fpage>620</fpage><lpage>625</lpage><pub-id pub-id-type="doi">10.1038/nature07008</pub-id><?supplied-pmid 18509436?><pub-id pub-id-type="pmid">18509436</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Mazmanian SK, Round JL, Kasper DL. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature. 2008;453(7195):620&#x02013;5.<pub-id pub-id-type="pmid">18509436</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Mazmanian</surname><given-names>SK</given-names></name><name><surname>Liu</surname><given-names>CH</given-names></name><name><surname>Tzianabos</surname><given-names>AO</given-names></name><name><surname>Kasper</surname><given-names>DL</given-names></name></person-group><article-title>An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system</article-title><source>Cell</source><year>2005</year><volume>122</volume><issue>1</issue><fpage>107</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2005.05.007</pub-id><?supplied-pmid 16009137?><pub-id pub-id-type="pmid">16009137</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Mazmanian SK, Liu CH, Tzianabos AO, Kasper DL. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell. 2005;122(1):107&#x02013;18.<pub-id pub-id-type="pmid">16009137</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Pritchard</surname><given-names>DM</given-names></name><name><surname>Watson</surname><given-names>AJ</given-names></name></person-group><article-title>Apoptosis and gastrointestinal pharmacology</article-title><source>Pharmacol Ther</source><year>1996</year><volume>72</volume><issue>2</issue><fpage>149</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1016/S0163-7258(96)00102-7</pub-id><?supplied-pmid 8981574?><pub-id pub-id-type="pmid">8981574</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Pritchard DM, Watson AJ. Apoptosis and gastrointestinal pharmacology. Pharmacol Ther. 1996;72(2):149&#x02013;69.<pub-id pub-id-type="pmid">8981574</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Rich</surname><given-names>T</given-names></name><name><surname>Watson</surname><given-names>CJ</given-names></name><name><surname>Wyllie</surname><given-names>A</given-names></name></person-group><article-title>Apoptosis: the germs of death</article-title><source>Nat Cell Biol</source><year>1999</year><volume>1</volume><issue>3</issue><fpage>E69</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1038/11038</pub-id><?supplied-pmid 10559914?><pub-id pub-id-type="pmid">10559914</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Rich T, Watson CJ, Wyllie A. Apoptosis: the germs of death. Nat Cell Biol. 1999;1(3):E69-71.<pub-id pub-id-type="pmid">10559914</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Ow</surname><given-names>YP</given-names></name><name><surname>Green</surname><given-names>DR</given-names></name><name><surname>Hao</surname><given-names>Z</given-names></name><name><surname>Mak</surname><given-names>TW</given-names></name></person-group><article-title>Cytochrome c: functions beyond respiration</article-title><source>Nat Rev Mol Cell Biol</source><year>2008</year><volume>9</volume><issue>7</issue><fpage>532</fpage><lpage>542</lpage><pub-id pub-id-type="doi">10.1038/nrm2434</pub-id><?supplied-pmid 18568041?><pub-id pub-id-type="pmid">18568041</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Ow YP, Green DR, Hao Z, Mak TW. Cytochrome c: functions beyond respiration. Nat Rev Mol Cell Biol. 2008;9(7):532&#x02013;42.<pub-id pub-id-type="pmid">18568041</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Kroemer</surname><given-names>G</given-names></name><name><surname>Dallaporta</surname><given-names>B</given-names></name><name><surname>Resche-Rigon</surname><given-names>M</given-names></name></person-group><article-title>The mitochondrial death/life regulator in apoptosis and necrosis</article-title><source>Annu Rev Physiol</source><year>1998</year><volume>60</volume><fpage>619</fpage><lpage>642</lpage><pub-id pub-id-type="doi">10.1146/annurev.physiol.60.1.619</pub-id><?supplied-pmid 9558479?><pub-id pub-id-type="pmid">9558479</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Kroemer G, Dallaporta B, Resche-Rigon M. The mitochondrial death/life regulator in apoptosis and necrosis. Annu Rev Physiol. 1998;60:619&#x02013;42.<pub-id pub-id-type="pmid">9558479</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>R</given-names></name><name><surname>Letai</surname><given-names>A</given-names></name><name><surname>Sarosiek</surname><given-names>K</given-names></name></person-group><article-title>Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins</article-title><source>Nat Rev Mol Cell Biol</source><year>2019</year><volume>20</volume><issue>3</issue><fpage>175</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1038/s41580-018-0089-8</pub-id><?supplied-pmid 30655609?><pub-id pub-id-type="pmid">30655609</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Singh R, Letai A, Sarosiek K. Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat Rev Mol Cell Biol. 2019;20(3):175&#x02013;93.<pub-id pub-id-type="pmid">30655609</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Arnoult</surname><given-names>D</given-names></name></person-group><article-title>Mitochondrial fragmentation in apoptosis</article-title><source>Trends Cell Biol</source><year>2007</year><volume>17</volume><issue>1</issue><fpage>6</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2006.11.001</pub-id><?supplied-pmid 17116393?><pub-id pub-id-type="pmid">17116393</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Arnoult D. Mitochondrial fragmentation in apoptosis. Trends Cell Biol. 2007;17(1):6&#x02013;12.<pub-id pub-id-type="pmid">17116393</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Bock</surname><given-names>FJ</given-names></name><name><surname>Tait</surname><given-names>SWG</given-names></name></person-group><article-title>Mitochondria as multifaceted regulators of cell death</article-title><source>Nat Rev Mol Cell Biol</source><year>2020</year><volume>21</volume><issue>2</issue><fpage>85</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1038/s41580-019-0173-8</pub-id><?supplied-pmid 31636403?><pub-id pub-id-type="pmid">31636403</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Bock FJ, Tait SWG. Mitochondria as multifaceted regulators of cell death. Nat Rev Mol Cell Biol. 2020;21(2):85&#x02013;100.<pub-id pub-id-type="pmid">31636403</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Porter</surname><given-names>AG</given-names></name><name><surname>J&#x000e4;nicke</surname><given-names>RU</given-names></name></person-group><article-title>Emerging roles of caspase-3 in apoptosis</article-title><source>Cell Death Differ</source><year>1999</year><volume>6</volume><issue>2</issue><fpage>99</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1038/sj.cdd.4400476</pub-id><?supplied-pmid 10200555?><pub-id pub-id-type="pmid">10200555</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Porter AG, J&#x000e4;nicke RU. Emerging roles of caspase-3 in apoptosis. Cell Death Differ. 1999;6(2):99&#x02013;104.<pub-id pub-id-type="pmid">10200555</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>Y</given-names></name></person-group><article-title>Mechanisms of caspase activation and inhibition during apoptosis</article-title><source>Mol Cell</source><year>2002</year><volume>9</volume><issue>3</issue><fpage>459</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.1016/S1097-2765(02)00482-3</pub-id><?supplied-pmid 11931755?><pub-id pub-id-type="pmid">11931755</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Shi Y. Mechanisms of caspase activation and inhibition during apoptosis. Mol Cell. 2002;9(3):459&#x02013;70.<pub-id pub-id-type="pmid">11931755</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Shalini</surname><given-names>S</given-names></name><name><surname>Dorstyn</surname><given-names>L</given-names></name><name><surname>Dawar</surname><given-names>S</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name></person-group><article-title>Old, new and emerging functions of caspases</article-title><source>Cell Death Differ</source><year>2015</year><volume>22</volume><issue>4</issue><fpage>526</fpage><lpage>539</lpage><pub-id pub-id-type="doi">10.1038/cdd.2014.216</pub-id><?supplied-pmid 25526085?><pub-id pub-id-type="pmid">25526085</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Shalini S, Dorstyn L, Dawar S, Kumar S. Old, new and emerging functions of caspases. Cell Death Differ. 2015;22(4):526&#x02013;39.<pub-id pub-id-type="pmid">25526085</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Roberti</surname><given-names>MP</given-names></name><name><surname>Yonekura</surname><given-names>S</given-names></name><name><surname>Duong</surname><given-names>CPM</given-names></name><name><surname>Picard</surname><given-names>M</given-names></name><name><surname>Ferrere</surname><given-names>G</given-names></name><name><surname>Tidjani Alou</surname><given-names>M</given-names></name><etal/></person-group><article-title>Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer</article-title><source>Nat Med</source><year>2020</year><volume>26</volume><issue>6</issue><fpage>919</fpage><lpage>931</lpage><pub-id pub-id-type="doi">10.1038/s41591-020-0882-8</pub-id><?supplied-pmid 32451498?><pub-id pub-id-type="pmid">32451498</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Roberti MP, Yonekura S, Duong CPM, Picard M, Ferrere G, Tidjani Alou M, et al. Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer. Nat Med. 2020;26(6):919&#x02013;31.<pub-id pub-id-type="pmid">32451498</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Mann</surname><given-names>ER</given-names></name><name><surname>Lam</surname><given-names>YK</given-names></name><name><surname>Uhlig</surname><given-names>HH</given-names></name></person-group><article-title>Short-chain fatty acids: linking diet, the microbiome and immunity</article-title><source>Nat Rev Immunol</source><year>2024</year><volume>24</volume><issue>8</issue><fpage>577</fpage><lpage>595</lpage><pub-id pub-id-type="doi">10.1038/s41577-024-01014-8</pub-id><?supplied-pmid 38565643?><pub-id pub-id-type="pmid">38565643</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Mann ER, Lam YK, Uhlig HH. Short-chain fatty acids: linking diet, the microbiome and immunity. Nat Rev Immunol. 2024;24(8):577&#x02013;95.<pub-id pub-id-type="pmid">38565643</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Lyu</surname><given-names>F</given-names></name><name><surname>Xiong</surname><given-names>Q</given-names></name><name><surname>Gu</surname><given-names>P</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Novel tripeptide RKH derived from Akkermansia muciniphila protects against lethal sepsis</article-title><source>Gut</source><year>2023</year><volume>73</volume><issue>1</issue><fpage>78</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2023-329996</pub-id><?supplied-pmid 37553229?><pub-id pub-id-type="pmid">37553229</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Xie S, Li J, Lyu F, Xiong Q, Gu P, Chen Y, et al. Novel tripeptide RKH derived from Akkermansia muciniphila protects against lethal sepsis. Gut. 2023;73(1):78&#x02013;91.<pub-id pub-id-type="pmid">37553229</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>Y</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>ZH</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Alam</surname><given-names>AM</given-names></name><name><surname>Haran</surname><given-names>JP</given-names></name><etal/></person-group><article-title>Bacteroides Fragilis in the gut microbiomes of Alzheimer's disease activates microglia and triggers pathogenesis in neuronal C/EBP&#x003b2; transgenic mice</article-title><source>Nat Commun</source><year>2023</year><volume>14</volume><issue>1</issue><fpage>5471</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-41283-w</pub-id><?supplied-pmid 37673907?><pub-id pub-id-type="pmid">37673907</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">Xia Y, Xiao Y, Wang ZH, Liu X, Alam AM, Haran JP, et al. Bacteroides Fragilis in the gut microbiomes of Alzheimer&#x02019;s disease activates microglia and triggers pathogenesis in neuronal C/EBP&#x003b2; transgenic mice. Nat Commun. 2023;14(1):5471.<pub-id pub-id-type="pmid">37673907</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Bae</surname><given-names>M</given-names></name><name><surname>Cassilly</surname><given-names>CD</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Park</surname><given-names>SM</given-names></name><name><surname>Tusi</surname><given-names>BK</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><etal/></person-group><article-title>Akkermansia muciniphila phospholipid induces homeostatic immune responses</article-title><source>Nature</source><year>2022</year><volume>608</volume><issue>7921</issue><fpage>168</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1038/s41586-022-04985-7</pub-id><?supplied-pmid 35896748?><pub-id pub-id-type="pmid">35896748</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">Bae M, Cassilly CD, Liu X, Park SM, Tusi BK, Chen X, et al. Akkermansia muciniphila phospholipid induces homeostatic immune responses. Nature. 2022;608(7921):168&#x02013;73.<pub-id pub-id-type="pmid">35896748</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>O'Toole</surname><given-names>PW</given-names></name><name><surname>Marchesi</surname><given-names>JR</given-names></name><name><surname>Hill</surname><given-names>C</given-names></name></person-group><article-title>Next-generation probiotics: the spectrum from probiotics to live biotherapeutics</article-title><source>Nat Microbiol</source><year>2017</year><volume>2</volume><fpage>17057</fpage><pub-id pub-id-type="doi">10.1038/nmicrobiol.2017.57</pub-id><?supplied-pmid 28440276?><pub-id pub-id-type="pmid">28440276</pub-id>
</element-citation><mixed-citation id="mc-CR51" publication-type="journal">O&#x02019;Toole PW, Marchesi JR, Hill C. Next-generation probiotics: the spectrum from probiotics to live biotherapeutics. Nat Microbiol. 2017;2:17057.<pub-id pub-id-type="pmid">28440276</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Bachem</surname><given-names>A</given-names></name><name><surname>Makhlouf</surname><given-names>C</given-names></name><name><surname>Binger</surname><given-names>KJ</given-names></name><name><surname>de Souza</surname><given-names>DP</given-names></name><name><surname>Tull</surname><given-names>D</given-names></name><name><surname>Hochheiser</surname><given-names>K</given-names></name><etal/></person-group><article-title>Microbiota-Derived Short-Chain Fatty Acids Promote the Memory Potential of Antigen-Activated CD8(+) T Cells</article-title><source>Immunity</source><year>2019</year><volume>51</volume><issue>2</issue><fpage>285</fpage><lpage>297.e285</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2019.06.002</pub-id><?supplied-pmid 31272808?><pub-id pub-id-type="pmid">31272808</pub-id>
</element-citation><mixed-citation id="mc-CR52" publication-type="journal">Bachem A, Makhlouf C, Binger KJ, de Souza DP, Tull D, Hochheiser K, et al. Microbiota-Derived Short-Chain Fatty Acids Promote the Memory Potential of Antigen-Activated CD8(+) T Cells. Immunity. 2019;51(2):285-297.e285.<pub-id pub-id-type="pmid">31272808</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Plovier</surname><given-names>H</given-names></name><name><surname>Everard</surname><given-names>A</given-names></name><name><surname>Druart</surname><given-names>C</given-names></name><name><surname>Depommier</surname><given-names>C</given-names></name><name><surname>Van Hul</surname><given-names>M</given-names></name><name><surname>Geurts</surname><given-names>L</given-names></name><etal/></person-group><article-title>A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice</article-title><source>Nat Med</source><year>2017</year><volume>23</volume><issue>1</issue><fpage>107</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1038/nm.4236</pub-id><?supplied-pmid 27892954?><pub-id pub-id-type="pmid">27892954</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">Plovier H, Everard A, Druart C, Depommier C, Van Hul M, Geurts L, et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat Med. 2017;23(1):107&#x02013;13.<pub-id pub-id-type="pmid">27892954</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Andresen</surname><given-names>V</given-names></name><name><surname>Gschossmann</surname><given-names>J</given-names></name><name><surname>Layer</surname><given-names>P</given-names></name></person-group><article-title>Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial</article-title><source>Lancet Gastroenterol Hepatol</source><year>2020</year><volume>5</volume><issue>7</issue><fpage>658</fpage><lpage>666</lpage><pub-id pub-id-type="doi">10.1016/S2468-1253(20)30056-X</pub-id><?supplied-pmid 32277872?><pub-id pub-id-type="pmid">32277872</pub-id>
</element-citation><mixed-citation id="mc-CR54" publication-type="journal">Andresen V, Gschossmann J, Layer P. Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial. Lancet Gastroenterol Hepatol. 2020;5(7):658&#x02013;66.<pub-id pub-id-type="pmid">32277872</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Depommier</surname><given-names>C</given-names></name><name><surname>Everard</surname><given-names>A</given-names></name><name><surname>Druart</surname><given-names>C</given-names></name><name><surname>Plovier</surname><given-names>H</given-names></name><name><surname>Van Hul</surname><given-names>M</given-names></name><name><surname>Vieira-Silva</surname><given-names>S</given-names></name><etal/></person-group><article-title>Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study</article-title><source>Nat Med</source><year>2019</year><volume>25</volume><issue>7</issue><fpage>1096</fpage><lpage>1103</lpage><pub-id pub-id-type="doi">10.1038/s41591-019-0495-2</pub-id><?supplied-pmid 31263284?><pub-id pub-id-type="pmid">31263284</pub-id>
</element-citation><mixed-citation id="mc-CR55" publication-type="journal">Depommier C, Everard A, Druart C, Plovier H, Van Hul M, Vieira-Silva S, et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med. 2019;25(7):1096&#x02013;103.<pub-id pub-id-type="pmid">31263284</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Succinate and mitochondrial DNA trigger atopic march from atopic dermatitis to intestinal inflammation</article-title><source>J Allergy Clin Immunol</source><year>2023</year><volume>151</volume><issue>4</issue><fpage>1050</fpage><lpage>1066.e1057</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2022.11.026</pub-id><?supplied-pmid 36587852?><pub-id pub-id-type="pmid">36587852</pub-id>
</element-citation><mixed-citation id="mc-CR56" publication-type="journal">Wang S, Liu B, Huang J, He H, Zhou L, He Y, et al. Succinate and mitochondrial DNA trigger atopic march from atopic dermatitis to intestinal inflammation. J Allergy Clin Immunol. 2023;151(4):1050-1066.e1057.<pub-id pub-id-type="pmid">36587852</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Kula-Alwar</surname><given-names>D</given-names></name><name><surname>Prag</surname><given-names>HA</given-names></name><name><surname>Krieg</surname><given-names>T</given-names></name></person-group><article-title>Targeting Succinate Metabolism in Ischemia/Reperfusion Injury</article-title><source>Circulation</source><year>2019</year><volume>140</volume><issue>24</issue><fpage>1968</fpage><lpage>1970</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.119.042791</pub-id><?supplied-pmid 31815541?><pub-id pub-id-type="pmid">31815541</pub-id>
</element-citation><mixed-citation id="mc-CR57" publication-type="journal">Kula-Alwar D, Prag HA, Krieg T. Targeting Succinate Metabolism in Ischemia/Reperfusion Injury. Circulation. 2019;140(24):1968&#x02013;70.<pub-id pub-id-type="pmid">31815541</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>KY</given-names></name><name><surname>Lei</surname><given-names>XY</given-names></name><name><surname>Wu</surname><given-names>DH</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>JQ</given-names></name><name><surname>Li</surname><given-names>QT</given-names></name><etal/></person-group><article-title>Akkermansia muciniphila protects the intestine from irradiation-induced injury by secretion of propionic acid</article-title><source>Gut Microbes</source><year>2023</year><volume>15</volume><issue>2</issue><fpage>2293312</fpage><pub-id pub-id-type="doi">10.1080/19490976.2023.2293312</pub-id><?supplied-pmid 38087436?><pub-id pub-id-type="pmid">38087436</pub-id>
</element-citation><mixed-citation id="mc-CR58" publication-type="journal">He KY, Lei XY, Wu DH, Zhang L, Li JQ, Li QT, et al. Akkermansia muciniphila protects the intestine from irradiation-induced injury by secretion of propionic acid. Gut Microbes. 2023;15(2):2293312.<pub-id pub-id-type="pmid">38087436</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name><surname>Haghikia</surname><given-names>A</given-names></name><name><surname>Zimmermann</surname><given-names>F</given-names></name><name><surname>Schumann</surname><given-names>P</given-names></name><name><surname>Jasina</surname><given-names>A</given-names></name><name><surname>Roessler</surname><given-names>J</given-names></name><name><surname>Schmidt</surname><given-names>D</given-names></name><etal/></person-group><article-title>Propionate attenuates atherosclerosis by immune-dependent regulation of intestinal cholesterol metabolism</article-title><source>Eur Heart J</source><year>2022</year><volume>43</volume><issue>6</issue><fpage>518</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehab644</pub-id><?supplied-pmid 34597388?><pub-id pub-id-type="pmid">34597388</pub-id>
</element-citation><mixed-citation id="mc-CR59" publication-type="journal">Haghikia A, Zimmermann F, Schumann P, Jasina A, Roessler J, Schmidt D, et al. Propionate attenuates atherosclerosis by immune-dependent regulation of intestinal cholesterol metabolism. Eur Heart J. 2022;43(6):518&#x02013;33.<pub-id pub-id-type="pmid">34597388</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name><surname>Duscha</surname><given-names>A</given-names></name><name><surname>Gisevius</surname><given-names>B</given-names></name><name><surname>Hirschberg</surname><given-names>S</given-names></name><name><surname>Yissachar</surname><given-names>N</given-names></name><name><surname>Stangl</surname><given-names>GI</given-names></name><name><surname>Dawin</surname><given-names>E</given-names></name><etal/></person-group><article-title>Propionic Acid Shapes the Multiple Sclerosis Disease Course by an Immunomodulatory Mechanism</article-title><source>Cell</source><year>2020</year><volume>180</volume><issue>6</issue><fpage>1067</fpage><lpage>1080.e1016</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.02.035</pub-id><?supplied-pmid 32160527?><pub-id pub-id-type="pmid">32160527</pub-id>
</element-citation><mixed-citation id="mc-CR60" publication-type="journal">Duscha A, Gisevius B, Hirschberg S, Yissachar N, Stangl GI, Dawin E, et al. Propionic Acid Shapes the Multiple Sclerosis Disease Course by an Immunomodulatory Mechanism. Cell. 2020;180(6):1067-1080.e1016.<pub-id pub-id-type="pmid">32160527</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name><surname>Ochoa-Rep&#x000e1;raz</surname><given-names>J</given-names></name><name><surname>Mielcarz</surname><given-names>DW</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Begum-Haque</surname><given-names>S</given-names></name><name><surname>Dasgupta</surname><given-names>S</given-names></name><name><surname>Kasper</surname><given-names>DL</given-names></name><etal/></person-group><article-title>A polysaccharide from the human commensal Bacteroides fragilis protects against CNS demyelinating disease</article-title><source>Mucosal Immunol</source><year>2010</year><volume>3</volume><issue>5</issue><fpage>487</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1038/mi.2010.29</pub-id><?supplied-pmid 20531465?><pub-id pub-id-type="pmid">20531465</pub-id>
</element-citation><mixed-citation id="mc-CR61" publication-type="journal">Ochoa-Rep&#x000e1;raz J, Mielcarz DW, Wang Y, Begum-Haque S, Dasgupta S, Kasper DL, et al. A polysaccharide from the human commensal Bacteroides fragilis protects against CNS demyelinating disease. Mucosal Immunol. 2010;3(5):487&#x02013;95.<pub-id pub-id-type="pmid">20531465</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name><surname>Round</surname><given-names>JL</given-names></name><name><surname>Mazmanian</surname><given-names>SK</given-names></name></person-group><article-title>Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota</article-title><source>Proc Natl Acad Sci U S A</source><year>2010</year><volume>107</volume><issue>27</issue><fpage>12204</fpage><lpage>12209</lpage><pub-id pub-id-type="doi">10.1073/pnas.0909122107</pub-id><?supplied-pmid 20566854?><pub-id pub-id-type="pmid">20566854</pub-id>
</element-citation><mixed-citation id="mc-CR62" publication-type="journal">Round JL, Mazmanian SK. Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc Natl Acad Sci U S A. 2010;107(27):12204&#x02013;9.<pub-id pub-id-type="pmid">20566854</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>